WO2019182910A1 - Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués - Google Patents

Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués Download PDF

Info

Publication number
WO2019182910A1
WO2019182910A1 PCT/US2019/022572 US2019022572W WO2019182910A1 WO 2019182910 A1 WO2019182910 A1 WO 2019182910A1 US 2019022572 W US2019022572 W US 2019022572W WO 2019182910 A1 WO2019182910 A1 WO 2019182910A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
chain
cells
isolated
immunoglobulin
Prior art date
Application number
PCT/US2019/022572
Other languages
English (en)
Inventor
Roderick A. Hyde
Wayne R. Kindsvogel
Gary L. Mcknight
Original Assignee
Elwha Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/924,898 external-priority patent/US10745468B2/en
Application filed by Elwha Llc filed Critical Elwha Llc
Priority to CN201980030908.8A priority Critical patent/CN112105641A/zh
Priority to EP19771532.9A priority patent/EP3768707A4/fr
Publication of WO2019182910A1 publication Critical patent/WO2019182910A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • compositions and methods are disclosed herein for producing an immunoglobulin in a recombinant B lymphocyte cell line.
  • Compositions and methods are disclosed herein for treating a disease in a vertebrate subject with an immunotherapeutic product.
  • the immunotherapeutic product can include the recombinant B lymphocyte cell line that produces one or more antibodies.
  • the immunotherapeutic product can include the recombinant B lymphocyte cell line that is an exceptional antigen presenting cell.
  • compositions and methods are disclosed for providing a therapeutically effective amount of one or more modified B lymphocytes to a patient suspected or known to have a disease, disorder, or condition of the immune system including, but not limited to, infectious disease, auto-immune disease, cancer, neuro-physiological disease or disorders, or other pathological conditions.
  • a cohort of modified B lymphocytes is provided, as described herein.
  • a monoclonal administration of modified B lymphocytes is provided, as described herein.
  • a polyclonal administration of modified B lymphocytes is provided, as described herein.
  • compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated modified B cell that may be part of a B lymphocyte cell line.
  • Compositions and methods are disclosed herein for producing one or more immunoglobulins in the isolated modified B cell or B lymphocyte cell line that direct cell signaling by membrane immunoglobulin in the isolated modified B cell or B lymphocyte cell line.
  • Immune cell therapy in a vertebrate subject can include administering to the vertebrate subject the isolated modified B cell or B lymphocyte cell line that synthesizes secreted immunoglobulins and membrane immunoglobulins each having different target antigens.
  • Immune cell therapy in a vertebrate subject can include administering to the vertebrate subject antigen presenting cells comprised of the isolated modified B cell or B lymphocyte cell line that direct antigen internalization and processing to produce exceptional antigen presenting cells.
  • the isolated modified B cell or B lymphocyte cell line can produce antigen presenting cells that are exceptional or superior at capturing, internalizing and presenting the antigen recognized by the endogenous or exogenously derived membrane immunoglobulin.
  • Compositions and methods are disclosed herein for treating a disease in a vertebrate subject with an immunotherapeutic product.
  • the immunotherapeutic product can include the isolated modified B cell or B lymphocyte cell line having an endogenously-derived or exogenously derived membrane immunoglobulin reactive to a first antigen (e.g., capable of binding to a first antigen) wherein the isolated modified B cell or B lymphocyte cell line produces one or more secreted immunoglobulins reactive to a second antigen or produces a reassigned biological agent.
  • a first antigen e.g., capable of binding to a first antigen
  • the isolated modified B cell or B lymphocyte cell line produces one or more secreted immunoglobulins reactive to a second antigen or produces a reassigned biological agent.
  • the immunotherapeutic product can include the isolated modified B cell or B lymphocyte cell line that can be a monoclonal B lymphocyte cell line or polyclonal B lymphocyte cell line that produces one or more secreted immunoglobulins.
  • the immunotherapeutic product can include the isolated B lymphocyte cell line that produces one or more secreted antibodies, e.g., antibodies that recognize different epitopes on the same antigen.
  • the immunotherapeutic product can include the isolated B lymphocyte cell line that produces reassigned biological agents (e.g., cytokines, cytotoxins, chemokines, receptors, ligands, immunomodulatory, immune effector molecules, transcription factors, etc.).
  • the immunotherapeutic product can include the isolated B lymphocyte cell line as one or more antigen presenting cells.
  • the reassigned biological agent can include an agent (such as a cytokine or ligand) that is typically not expressed by naturally occurring B lymphocytes, or is not expressed under certain circumstances or conditions by naturally occurring B
  • Our modified B lymphocytes are able to express the reassigned biological agent due to the engineering of that B lymphocyte, which may include constitutive expression of the reassigned biological agent, or may include inductive expression under specific circumstances or conditions (for example,“triggering” of expression by receptor/ligand binding on the surface of the modified B lymphocyte).
  • the isolated B lymphocyte cell line can include an immunotherapeutic product administered to a vertebrate subject to develop long-lived isolated B lymphocytes in the vertebrate subject for immune surveillance of chronic disease.
  • the immunotherapeutic product can include the isolated B lymphocyte cell line having a reassigned biological agent to modulate immunity for therapy of chronic or acute disease (for example, IL-10 for multiple sclerosis or IL-2 for influenza).
  • the immunotherapeutic product can include the isolated B lymphocyte cell line having an endogenously-derived or exogenously derived membrane immunoglobulin that can be administered to a vertebrate subject to provide an antigen presenting cell to the vertebrate subject.
  • an isolated modified B cell includes at least one reassigned biological agent incorporated at an active Ig gene location (e.g., H or L chain) in a memory B cell.
  • the reassigned biological agent is under the control of the Ig promoter/enhancer elements and the endogenous antibody (secreted and/or membrane) of the isolated modified B cell is disrupted.
  • the isolated modified B cell has an exogenous membrane Ig (B cell receptor) that binds to an antigen and induces expression of the reassigned biological agent.
  • the exogenous membrane Ig (B cell receptor) and reassigned biological agent can both be expressed at the same active Ig locus (e.g., H chain).
  • An isolated cell line as described herein can include an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane
  • the isolated B lymphocyte cell line is capable of expressing at least one endogenous membrane immunoglobulin reactive to the second antigen.
  • the at least one exogenously incorporated membrane immunoglobulin can include one or more exogenously incorporated membrane immunoglobulin polypeptides.
  • the at least one exogenously incorporated membrane immunoglobulin can include at least one exogenously incorporated nucleic acid encoding the at least one membrane immunoglobulin, wherein the cell line is capable of expressing the at least one membrane immunoglobulin.
  • the at least one exogenously incorporated membrane immunoglobulin comprises at least two exogenously incorporated nucleic acid encoding the at least one membrane immunoglobulin.
  • the at least one exogenously incorporated membrane immunoglobulin can include nucleic acids encoding two heavy chain (H) immunoglobulins and two light chain (L) immunoglobulins.
  • the at least one exogenously incorporated membrane immunoglobulin can include nucleic acids encoding one heavy chain (H) immunoglobulin and one light chain (L) immunoglobulin.
  • the at least one exogenously incorporated membrane immunoglobulin can include nucleic acids encoding one single chain Fv (SCFv) immunoglobulin (e.g., SCFv fused with immunoglobulin constant region domains).
  • SCFv single chain Fv
  • the exogenously incorporated nucleic acid encoding the at least one membrane immunoglobulin can be present in one or more chromosomal loci in the isolated B lymphocyte cell line.
  • the exogenously incorporated nucleic acid in the isolated B lymphocyte cell line is capable of disrupting expression of the endogenous immunoglobulin. For example, disruption of endogenous H or L chain expression may knock out production of member IgG and/or secreted IgG and more generally may knock out endogenous antibody synthesis.
  • immunoglobulin, exogenously incorporated secreted immunoglobulin, or exogenously incorporated cytotoxicity effector molecule at an active site allows for a hijacking of the endogenous machinery (e.g., upon rearrangement of the regions, the promoter and enhancer elements are brought into close proximity).
  • the at least two exogenously incorporated nucleic acids encoding the at least one of the membrane immunoglobulin can be present in Ig H chain and Ig L chain
  • the at least one exogenously incorporated nucleic acid encoding the at least one membrane immunoglobulins can be present in one or more non-Ig L chain or non-Ig H chain chromosomal loci in the isolated B lymphocyte cell line.
  • the at least one exogenously incorporated nucleic acid encoding the at least one membrane immunoglobulin can be present in an extrachromosomal replicating genetic element in the isolated B lymphocyte cell line.
  • the immunoglobulin can be derived from a B lymphocyte cell line.
  • the at least one exogenously incorporated membrane immunoglobulin activated by the first antigen is capable of controlling expression of the at least one endogenous secreted immunoglobulin reactive to the second antigen.
  • the isolated B lymphocyte cell line can include at least one of naive B lymphocyte, immature B lymphocyte, transitional B lymphocyte, mature B lymphocyte, Bl B lymphocyte, marginal zone B lymphocyte, follicular B lymphocyte, memory B lymphocyte, plasmablast, or plasma cell.
  • the isolated B lymphocyte cell line can include a polyclonal population of B lymphocytes.
  • the isolated B lymphocyte cell line can include a monoclonal population of B lymphocytes.
  • immunoglobulin can include at least one of a membrane anchor, a cytoplasmic domain, a hinge region and an extracellular ligand-binding domain.
  • the exogenously incorporated nucleic acid encoding the at least one membrane immunoglobulin can be integrated into one or more locations along the genes encoding the B cell receptor. In an embodiment, the exogenously incorporated nucleic acid encoding the at least one membrane immunoglobulin can be integrated into one or more locations in the Ig loci (e.g., the heavy chain or light chain immunoglobulins as described above).
  • An isolated recombinant cell line as described herein can include an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding secreted immunoglobulin reactive to a second antigen.
  • the isolated B lymphocyte cell line is capable of expressing at least one exogenously incorporated nucleic acid encoding membrane immunoglobulin reactive to the second antigen.
  • the isolated B lymphocyte cell line is capable of expressing at least one exogenously incorporated nucleic acid encoding a secreted immunoglobulin reactive to a third antigen.
  • the second antigen and the third antigen can be different epitopes of a single antigenic polypeptide.
  • the at least one exogenously incorporated membrane immunoglobulin can include at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding secreted immunoglobulin reactive
  • the at least one exogenously incorporated membrane immunoglobulin can include at least one exogenously incorporated nucleic acid encoding at least one membrane immunoglobulin polypeptide, wherein the cell line is capable of expressing the at least one membrane immunoglobulin polypeptide.
  • the immunoglobulin can be present in one or more chromosomal loci in the isolated B lymphocyte cell line.
  • the at least two exogenously incorporated nucleic acids encoding the at least one membrane immunoglobulins can be present in Ig H chain and Ig L chain chromosomal loci in the isolated B lymphocyte cell line.
  • the at least one exogenously incorporated nucleic acids encoding the at least one membrane immunoglobulin can be present in one or more non-Ig L or non-Ig H chromosomal loci in the isolated B lymphocyte cell line.
  • the at least one exogenously incorporated nucleic acids encoding the at least one membrane immunoglobulin can be present in an extrachromosomal replicating genetic element in the isolated B lymphocyte cell line.
  • the nucleic acid encoding the at least one membrane immunoglobulin can be derived from a B lymphocyte cell line.
  • the at least one exogenously incorporated membrane immunoglobulin activated by the first antigen is capable of controlling expression of the at least one exogenously incorporated secreted immunoglobulin reactive to the second antigen.
  • the isolated B lymphocyte cell line can include at least one of naive B lymphocyte, immature B lymphocyte, transitional B lymphocyte, mature B lymphocyte, Bl B lymphocyte, marginal zone B lymphocyte, follicular B lymphocyte, memory B lymphocyte, plasmablast, or plasma cell.
  • the isolated B lymphocyte cell line can include a polyclonal population of B lymphocytes.
  • the isolated B lymphocyte cell line can include a monoclonal population of B lymphocytes.
  • the membrane immunoglobulin can include at least one of a membrane anchor, a cytoplasmic domain, a hinge region, and an extracellular ligand-binding domain.
  • a modified B lymphocyte includes structural or functional features for exhibiting cellular cytotoxicity.
  • a modified B lymphocyte cell or cell line produces one or more antibodies and has one or more B cell receptors (membrane immunoglobulins as described herein)that are specific to target antigens, such as tumor antigens (including but not limited to, antigens that are mutant forms of“normal” cellular antigens, as well as antigens that are modified by way of post- translational modifications, and antigens that are expressed in an abnormal way or in an abnormal level).
  • a modified B lymphocyte cell or cell line is capable of mounting a complete immune response with both humoral as well as cellular immune components.
  • cytotoxicity expression can include secreted antibody or antibodies. Cytotoxicity expression can also include direct cell-to-cell contact that induces death (e.g., by lysis, necrosis, apoptosis, etc.).
  • the target cells include cancer cells (e.g., tumor or other cancer cells).
  • the target cells include cells that are related to autoimmune disease or infection.
  • the target cells include donor or host cells that are reactive to donor cells from a cell, tissue, or organ transplant (e.g., graft- versus-host disease).
  • the target cells include cells related to
  • a method for producing an immunoglobulin in an isolated B lymphocyte cell line as described herein can include isolating from a vertebrate subject exposed to, e.g., by infection, or immunized with at least one second antigen, a B lymphocyte cell line expressing at least one endogenous secreted immunoglobulin reactive to the at least one second antigen; introducing into the isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce a recombinant B lymphocyte cell line; and selecting the isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen and expressing the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen.
  • the method of claim can include administering the at least one first antigen to stimulate the recombinant B lymphocyte cell line; and assessing production of the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen in the recombinant B lymphocyte cell line.
  • immunoglobulin reactive to the at least one first antigen can include introducing at least one exogenous membrane immunoglobulin polypeptide reactive to the at least one first antigen.
  • Introducing into the at least one isolated recombinant B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to the at least one first antigen can include introducing at least one exogenous nucleic acid encoding at least one membrane immunoglobulin reactive to the at least one first antigen.
  • the method can include exposing the recombinant B lymphocyte cell line to the at least one first antigen to activate the recombinant B lymphocyte cell line to express the endogenous secreted immunoglobulin reactive to the at least one second antigen.
  • the method can include isolating the endogenous secreted immunoglobulin reactive to the at least one second antigen from the recombinant B lymphocyte cell line or from a culture of the recombinant B lymphocyte cell line. In the method, activating the at least one exogenously
  • the isolated B lymphocyte cell line can include at least one of naive B lymphocytes, immature B lymphocytes, transitional B lymphocytes, mature B lymphocytes, follicular B lymphocytes, memory B lymphocytes, plasmablasts, or plasma cells.
  • the isolated B lymphocyte cell line can include at least one memory B lymphocyte.
  • the isolated B lymphocyte cell line that has been modified by way of a chimeric B cell receptor or recombinant B cell receptor includes utilizing scFv fragments in construction of the modified B cell receptor.
  • transcription factors can also be constructed (e.g., on a separate vector) to be part of the modified B cell line(s).
  • a method for treating a subject that is afflicted with a disease or disorder includes administering a therapeutically effective amount of an isolated modified B lymphocyte cell line as disclosed herein. It is recognized that a therapeutically effective amount of cells to be given to a subject can be determined utilizing standard methods for immunotherapy and cell therapy programs.
  • a method for treating a disease in a vertebrate subject with an immunotherapeutic product as described herein can include isolating from a vertebrate subject exposed to, e.g ., by infection, or immunized with at least one second antigen, a B lymphocyte cell line expressing at least one endogenous secreted immunoglobulin reactive to the at least one second antigen; introducing into the isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce a recombinant B lymphocyte cell line; and selecting the recombinant B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen and expressing the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen for administration to one or more vertebrate subjects.
  • the method can include administering the at least one first antigen to stimulate the recombinant B lymphocyte cell line; and testing for the presence of the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen in the recombinant B lymphocyte cell line.
  • the method can include administering to the vertebrate subject a pharmaceutical composition including the isolated B lymphocyte cell line; and administering to the vertebrate subject the at least one first antigen to stimulate the isolated B lymphocyte cell line to produce the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen.
  • the method can include confirming the presence of the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen in a bloodstream of the vertebrate subject.
  • the method can include administering the at least one first antigen to stimulate the recombinant B lymphocyte cell line; testing for the presence of the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen; and administering to the vertebrate subject a pharmaceutical composition including the stimulated recombinant B lymphocyte cell line.
  • the recombinant B lymphocyte cell line can be autologous to one of the one or more vertebrate subjects.
  • the recombinant B lymphocyte cell line can be allogeneic to the one or more vertebrate subjects.
  • a method for producing at least one immunoglobulin in an isolated cell line as described herein can include introducing into at least one isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce at least one first isolated B lymphocyte cell line; selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen; introducing into the at least one first isolated B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one second antigen to produce at least one isolated recombinant B lymphocyte cell line; and selecting the at least one isolated recombinant B lymphocyte cell line expressing the one or more secreted immunoglobulin reactive to the at least one second antigen.
  • the method can include selecting the at least one isolated recombinant B lymphocyte cell line expressing the at least one exogenous membrane immunoglobulin reactive to the at least one first antigen.
  • the method can include administering the at least one first antigen to stimulate the at least one isolated recombinant B lymphocyte cell line; and testing for the presence of the one or more secreted immunoglobulins reactive to the at least one second antigen in the at least one isolated recombinant B lymphocyte cell line.
  • the method can include introducing into the at least one first isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to the at least one second antigen.
  • the method can include introducing into the at least one isolated recombinant B lymphocyte cell line at least one exogenous nucleic acid sequence encoding one or more secreted immunoglobulins reactive to at least one third antigen to produce at least one isolated second recombinant B lymphocyte cell line; and selecting the at least one isolated second recombinant B lymphocyte cell line expressing the at least one secreted
  • the method can include administering the at least one first antigen to stimulate the at least one isolated second recombinant B lymphocyte cell line; and testing for the presence of the at least one exogenous secreted immunoglobulin reactive to the at least one third antigen in the recombinant B lymphocyte cell line.
  • introducing into the at least one isolated B lymphocyte cell line the at least one exogenous membrane immunoglobulin reactive to the at least one first antigen can include introducing at least one exogenous membrane immunoglobulin reactive to the at least one first antigen.
  • Introducing into the at least one isolated B lymphocyte cell line the at least one exogenous membrane immunoglobulin reactive to the at least one first antigen can include introducing an exogenous nucleic acid encoding at least one membrane immunoglobulin reactive to the at least one first antigen.
  • Introducing into the at least one first isolated B lymphocyte cell line the at least one exogenous membrane immunoglobulin reactive to the at least one second antigen can include introducing at least one exogenous membrane immunoglobulin polypeptide reactive to the at least one second antigen.
  • immunoglobulin reactive to the at least one second antigen can include introducing at least one exogenous nucleic acid encoding at least one membrane immunoglobulin reactive to the at least one second antigen.
  • the method can include exposing the at least one isolated recombinant B lymphocyte cell line to the at least one first antigen, and testing for the activation of the at least one isolated recombinant B lymphocyte cell line to express the exogenous secreted immunoglobulin reactive to the at least one second antigen.
  • the method can include isolating the exogenous secreted immunoglobulin reactive to the at least one second antigen from the at least one isolated recombinant B lymphocyte cell line or from a culture of the at least one isolated recombinant B lymphocyte cell line.
  • activating the at least one exogenously incorporated membrane immunoglobulin with the first antigen is capable of controlling expression of the at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to the second antigen.
  • the at least one isolated B lymphocyte cell line can include at least one of naive B lymphocytes, immature B lymphocytes, transitional B lymphocytes, mature B lymphocytes, marginal zone B lymphocytes, Bl B lymphocytes, follicular B lymphocytes, memory B lymphocytes, plasmablasts, or plasma cells.
  • the at least one isolated B lymphocyte cell line can include at least one memory B lymphocyte.
  • a method for treating a disease in a vertebrate subject with an immunotherapeutic product as described herein can include introducing into at least one isolated B
  • lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce at least one first isolated B lymphocyte cell line; selecting the at least one first isolated B lymphocyte cell line expressing the membrane
  • the method can include selecting the at least one isolated recombinant B lymphocyte cell line expressing the at least one exogenous membrane immunoglobulin reactive to the at least one first antigen.
  • the method can include administering the at least one first antigen to stimulate the at least one isolated recombinant B lymphocyte cell line; and testing for the presence of the one or more secreted immunoglobulin reactive to the at least one second antigen in the at least one isolated recombinant B lymphocyte cell line.
  • the method can include administering to the vertebrate subject a pharmaceutical composition including the at least one isolated recombinant B lymphocyte cell line; and administering to the vertebrate subject the at least one first antigen to stimulate the at least one isolated recombinant B lymphocyte cell line to produce the one or more exogenous secreted immunoglobulin reactive to the at least one second antigen.
  • the method can include confirming the presence of the at least one exogenous secreted immunoglobulin reactive to the at least one second antigen in a bloodstream of the vertebrate subject.
  • the method can include administering the at least one first antigen to stimulate the at least one isolated recombinant B lymphocyte cell line to produce the one or more exogenous secreted immunoglobulin reactive to the at least one second antigen; and administering to the vertebrate subject a pharmaceutical composition including the stimulated at least one isolated recombinant B lymphocyte cell line.
  • the method can include introducing into the at least one first isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to the at least one second antigen.
  • the method can include introducing into the at least one isolated recombinant B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one third antigen to produce at least one isolated second recombinant B lymphocyte cell line; and selecting the at least one isolated second recombinant B lymphocyte cell line expressing at least one of the secreted immunoglobulin reactive to the at least one second antigen and the secreted immunoglobulin reactive to the at least one third antigen.
  • the method can include administering to the vertebrate subject a pharmaceutical composition including the at least one isolated second recombinant B lymphocyte cell line; and administering to the vertebrate subject the at least one first antigen to stimulate the at least one isolated second recombinant B lymphocyte cell line to produce the one or more exogenous secreted immunoglobulin reactive to the at least one second antigen and the one or more exogenous secreted immunoglobulin reactive to the at least one third antigen.
  • the method can include confirming the presence of the at least one exogenous secreted immunoglobulin reactive to the at least one second antigen and the one or more exogenous secreted immunoglobulin reactive to the at least one third antigen in a bloodstream of the vertebrate subject.
  • the method can include administering to the vertebrate subject the at least one first antigen to stimulate the at least one isolated second recombinant B lymphocyte cell line to produce the one or more exogenous secreted immunoglobulin reactive to the at least one second antigen and the one or more exogenous secreted immunoglobulin reactive to the at least one third antigen; and administering to the vertebrate subject a pharmaceutical composition including the stimulated at least one isolated second recombinant B lymphocyte cell line.
  • the recombinant B lymphocyte cell line can be autologous to one of the one or more vertebrate subjects.
  • the recombinant B lymphocyte cell line can be allogeneic to the one or more vertebrate subjects.
  • a method for producing at least one immunoglobulin in an isolated cell line as described herein can include introducing into at least one first isolated B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one first antigen to produce at least one isolated recombinant B lymphocyte cell line; selecting the at least one isolated recombinant B lymphocyte cell line expressing the one or more secreted immunoglobulin reactive to the at least one first antigen; introducing into the at least one isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one second antigen to produce at least one first isolated B lymphocyte cell line; and selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one second antigen.
  • a method for treating a disease in a vertebrate subject with an immunotherapeutic product as described herein can include introducing into at least one first isolated B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one first antigen to produce at least one isolated recombinant B lymphocyte cell line; selecting the at least one isolated recombinant B lymphocyte cell line expressing the secreted one or more immunoglobulin reactive to the at least one first antigens; introducing into the at least one isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one second antigen to produce at least one first isolated B lymphocyte cell line; and selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one second antigen for administration to the vertebrate subject.
  • FIGURE 1 is a schematic of a diagrammatic view of hypothetical immunoglobulin genes for memory B lymphocytes.
  • FIGURES 2A, 2B, 2C are a schematic of a diagrammatic view of nonfunctional and functional immunoglobulin heavy chain genes on chromosomes 14.
  • FIGURES 3A, 3B, 3C are a schematic of a diagrammatic view of replacement at immunoglobulin loci with heavy chain genes to express membrane IgG and secreted IgG.
  • FIGURES 4A, 4B, 4C, 4D are a schematic of a diagrammatic view of protocols to produce recombinant B lymphocytes with membrane immunoglobulin to a first antigen and secreted immunoglobulin to a second antigen.
  • FIGURE 5 is a schematic of a diagrammatic view of a method for producing an immunoglobulin in an isolated B lymphocyte cell line.
  • FIGURE 6 is a schematic of a diagrammatic view of a method for producing an immunoglobulin in an isolated B lymphocyte cell line.
  • FIGURE 7 is a schematic of a diagrammatic view of a method for producing an immunoglobulin in an isolated B lymphocyte cell line.
  • FIGURE 8A is a schematic of a diagrammatic view of a recombinant B cell receptor protein.
  • FIGURE 8B is a schematic of a diagrammatic view of a recombinant B cell receptor expression vector.
  • FIGURE 8C is a schematic of a diagrammatic view of chromosome 14 with inserted gene.
  • FIGURE 8D is a schematic of a diagrammatic view of an expression vector with transcription factors.
  • FIGURE 9A is a schematic of a diagrammatic view of an example of integration of a desired expression construct at an endogenous site (light chain Ig).
  • FIGURE 9B is a schematic of a diagrammatic view of an example of integration of a desired expression construct at an endogenous site (heavy chain Ig).
  • FIGURE 10 is a schematic of a diagrammatic view of a modified B cell engineered to selectively engage a surface immunoglobulin with a first target antigen and subsequently secrete a predetermined antibody to a second target antigen with optional secretion of a reassigned biological agent and/or cytotoxic effector molecule(s).
  • FIGURE 11 is a schematic of a diagrammatic view of a lymph node with modified B cells having reactivity to selective antigens, as determined by the particular
  • FIGURE 12A is a schematic of a diagrammatic view of an example of integration of a desired expression construct at an endogenous site (Heavy Chain Ig).
  • FIGURE 12B is a schematic of a diagrammatic view of an example of an expression vector for use in modifying B cells as described herein.
  • FIGURE 13 is a schematic of a diagrammatic view of an example of an integration of a desired bicistronic expression construct at an endogenous site (Heavy Chain Ig).
  • compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line.
  • Compositions and methods are disclosed herein for producing one or more immunoglobulins in the isolated B lymphocyte cell line that direct cell signaling by membrane immunoglobulin in the isolated B lymphocyte cell line.
  • Immune cell therapy in a vertebrate subject can include
  • Immune cell therapy in a vertebrate subject can include administering to the vertebrate subject antigen presenting cells comprised of the isolated B lymphocyte cell line that directs antigen internalization and processing to produce exceptional antigen presenting cells.
  • the isolated B lymphocyte cell line can produce antigen presenting cells that are exceptional or superior at capturing, internalizing and presenting the antigen recognized by the endogenous or exogenously derived membrane immunoglobulin.
  • the immunotherapeutic product can include the isolated B lymphocyte cell line having an endogenously-derived or exogenously derived membrane immunoglobulin reactive to a first antigen wherein the isolated B lymphocyte cell line produces one or more secreted immunoglobulins reactive to a second antigen.
  • the immunotherapeutic product can include the isolated B lymphocyte cell line that can be a monoclonal B lymphocyte cell line or polyclonal B lymphocyte cell line that produces one or more secreted antibodies and/or a reassigned biological agent.
  • the immunotherapeutic product can include the isolated B lymphocyte cell line that produces one or more secreted antibodies, e.g ., antibodies that recognize different epitopes on the same antigen.
  • the immunotherapeutic product can include the isolated B lymphocyte cell line as one or more antigen presenting cells.
  • the isolated B lymphocyte cell line can include an immunotherapeutic product administered to a vertebrate subject to develop long-lived isolated B lymphocytes in the vertebrate subject for immune surveillance of chronic disease.
  • the immunotherapeutic product can include the isolated B lymphocyte cell line having an endogenously-derived or exogenously derived membrane immunoglobulin that can be administered to a vertebrate subject to provide an antigen presenting cell to the vertebrate subject.
  • An isolated cell line as described herein can include an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane
  • the at least one exogenously incorporated membrane immunoglobulin can include an exogenously incorporated membrane immunoglobulin polypeptide.
  • the at least one exogenously incorporated membrane immunoglobulin can include an exogenously incorporated nucleic acid encoding a membrane immunoglobulin polypeptide, wherein the cell line is capable of expressing the membrane immunoglobulin polypeptide.
  • An isolated recombinant cell line as described herein can include an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding secreted immunoglobulin reactive to a second antigen.
  • An isolated recombinant cell line as described herein can include an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated gene integrated at an active, rearranged immunoglobulin gene under the control of
  • immunoglobulin variable region promoters and immunoglobulin enhancers For example, expression of a gene for a reassigned biological agent integrated at a rearranged immunoglobulin H-chain gene under the control of a variable heavy chain promoter and the immunoglobulin mu enhancer.
  • An isolated recombinant B cell line as described herein can include the capability of expressing a reassigned biological agent, such as a protein, glycoprotein, proteoglycan, nucleic acid (RNA, DNA, PNA, etc.), or other biological agent that is not ordinarily expressed from the Ig chromosomal loci for Ig H-chain and Ig L-chain in a naturally occurring B cell.
  • a reassigned biological agent such as a protein, glycoprotein, proteoglycan, nucleic acid (RNA, DNA, PNA, etc.)
  • the recombinant B cells described herein can include the capability of expressing at least one cytokine, cytokine receptor, small molecule, protein, monosaccharide, disaccharide, polysaccharide, or other biological agent.
  • the reassigned biological agent can include at least one enzyme, G-protein- coupled receptor, or ligand.
  • the reassigned biological agent can include at least one of tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL/ Apo2L), OX-40, CD95 (FasL/Apo-lL), gamma interferon (g-IFN), perforin, interleukin-21 (IL-21), IL-12, IL-15, IL-10, IL-22, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL- 12, IL-15, IL-17, IL-18, IL-23, pathogen-associated molecular patterns (PAMPs), damage- associated molecular patterns (DAMPs), CXCL-l, CXC, CC, GM-CSF, G-CSF, M-CSF, stem cell factor, TGF-beta, INFgamm
  • the reassigned biological agent can include at least one of a tumor-associated antigen, cell surface antigen or viral antigen.
  • tumor associated antigens can include: MUC-l, MUC-16, prostate cancer membrane antigen (PCMA), epidermal growth factor receptor 2 (HER2), B cell maturation antigen (BCMA), CD38, CD30, MAGE Al, NY-ESO-l and CD44v6.
  • Viral antigens can include: HIV-l proteins: gag, env, gp4l, gpl20, RNA-dependent DNA polymerase; influenza hemagglutinin; and hepatitis C virus proteins: NS3, NS4 and NS5.
  • the reassigned biological agent includes a bacterial component configured to induce other B cells to become IgA producing plasma cells.
  • the isolated modified B cell is utilized in the gut of a subject to work cooperatively or competitively with the microbiome in order to maintain health or alter a disease state in the subject. See e.g., Shi et al., Mil. Med. Res. 2017; 4: 14, online Apr 27, 2017, which is incorporated herein by reference.
  • the disease state includes disease that affects the gut.
  • the disease state includes disease that affects another system of the subject’s body, including a system disease.
  • expression of an agent can be initiated by engagement of the modified B cell’s immunoglobulin receptor (BCR).
  • BCR immunoglobulin receptor
  • transcription of the reassigned biological agent is initiated in the cascade of events following appropriate antigen binding occurring with the modified B cell’s BCR as described.
  • Antigen binding to membrane IgG leads to tyrosine phosphorylation on Iga and 3 ⁇ 4b (signal transduction proteins comprising the BCR) which initiate signaling pathways that activate and translocate intracellular messengers and transcription factors (e.g., NF-AT, Ras/Erk,
  • the modified B lymphocyte is modified to express at least one reassigned biological agent without further modification.
  • the modified B lymphocyte is modified to constitutively express the at least one reassigned biological agent.
  • the reassigned biological agent includes secreted molecules (e.g., cytokines, chemokines, cytotoxins, etc.) and can play a role in a larger secreted molecules (e.g., cytokines, chemokines, cytotoxins, etc.) and can play a role in a larger
  • the modified B lymphocyte is modified to inductively express the at least one reassigned biological agent (e.g., expression of the at least one reassigned biological agent can be driven by receptor- ligand binding, by transcription factor, by protein production of another biological reaction, etc.).
  • the modified B lymphocyte is also modified in other ways as described herein (e.g., to express an exogenous membrane immunoglobulin receptor and/or to express an exogenous secreted immunoglobulin receptor and/or to express cytotoxic agents, etc.).
  • the reassigned biological agent can include an agent that a naturally occurring B lymphocyte would not ordinarily express at all but due to its modification, the modified B lymphocyte is capable of expressing the reassigned biological agent.
  • the reassigned biological agent can include an agent that a naturally occurring B lymphocyte would not ordinarily express in specific circumstances or conditions but due to its modification, the modified B lymphocyte is capable of expressing the reassigned biological agent under those specific circumstances or conditions.
  • a naturally occurring regulatory B lymphocyte expresses and secretes IL-10 or TFG-beta 1
  • a naturally occurring effector B lymphocyte produces cytokines such as IL-2, IL-4,
  • TNF alpha, IL-6, or INFgamma TNF alpha, IL-6, or INFgamma.
  • the determination of a regulatory B lymphocyte or effector B lymphocyte is based on the exposure of those particular cells to antigen and/or other cytokines and immune modulators. ⁇ See, e.g., Lund, Curr. Opin. Immunol. 2008 June; 20(3):332-338, which is incorporated by reference herein.)
  • a B lymphocyte that would (under naturally occurring circumstances) express IL-2 can instead be modified to secrete IL-10, for example.
  • the IL-10 would fulfill the role of a reassigned biological agent.
  • IL-2 would fulfill the role of a reassigned biological agent.
  • the modification of a reassigned biological agent acts as a powerful tool to direct immune responses both in the modified B lymphocytes themselves, as well as the other players in the immune reaction (epithelial cells, neurons, other immune cells, etc.).
  • tumor immunology e.g., tumor suppression of standard immune response to tumor antigens
  • infectious disease e.g., viral evasion of standard immune surveillance
  • autoimmunity e.g., heightened inflammation or highly reactive immune response to“self’ or“no danger” antigens
  • a method for producing an immunoglobulin in an isolated B lymphocyte cell line as described herein can include isolating from a vertebrate subject exposed to, e.g., by infection, or immunized with at least one second antigen, a B lymphocyte cell line expressing at least one endogenous secreted immunoglobulin reactive to the at least one second antigen; introducing into the isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce a recombinant B lymphocyte cell line; and selecting the isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen and expressing the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen.
  • the modification A method for treating a disease in a vertebrate subject with an immunotherapeutic product as described herein can include isolating from a vertebrate subject exposed to, e.g ., by infection, or immunized with at least one second antigen, a B lymphocyte cell used to generate a cell line expressing at least one endogenous secreted immunoglobulin reactive to the at least one second antigen; introducing into the isolated B lymphocyte cell at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce a recombinant B lymphocyte cell line; and selecting the recombinant B
  • lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen and expressing the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen for administration to one or more vertebrate subjects.
  • a method for producing at least one immunoglobulin in an isolated cell line as described herein can include introducing into at least one isolated B lymphocyte cell at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce at least one first isolated B lymphocyte cell line; selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen; introducing into the at least one first isolated B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one second antigen to produce at least one isolated recombinant B lymphocyte cell line; and selecting the at least one isolated recombinant B lymphocyte cell line expressing the one or more secreted immunoglobulin reactive to the at least one second antigen.
  • a method for treating a disease in a vertebrate subject with an immunotherapeutic product as described herein can include introducing into at least one isolated B
  • lymphocyte cell at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce at least one first isolated B lymphocyte cell line; selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen; introducing into the at least one first isolated B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one second antigen to produce at least one isolated recombinant B lymphocyte cell line; selecting the at least one isolated recombinant B lymphocyte cell line expressing the secreted one or more immunoglobulin reactive to the at least one second antigens for administration to one or more vertebrate subjects.
  • a method for producing at least one immunoglobulin in an isolated cell line as described herein can include introducing into at least one first isolated B lymphocyte cell at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one first antigen to produce at least one isolated recombinant B lymphocyte cell line; selecting the at least one isolated recombinant B lymphocyte cell line expressing the one or more secreted immunoglobulin reactive to the at least one first antigen; introducing into the at least one isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one second antigen to produce at least one first isolated B lymphocyte cell line; and selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one second antigen.
  • a method for treating a disease in a vertebrate subject with an immunotherapeutic product as described herein can include introducing into at least one first isolated B lymphocyte cell at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one first antigen to produce at least one isolated recombinant B lymphocyte cell line; selecting the at least one isolated recombinant B lymphocyte cell line expressing the secreted one or more immunoglobulin reactive to the at least one first antigens; introducing into the at least one isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one second antigen to produce at least one first isolated B lymphocyte cell line; and selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one second antigen for administration to the vertebrate subject.
  • An isolated recombinant cell line includes an isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to a second antigen.
  • a modified B lymphocyte includes structural or functional features for exhibiting cellular cytotoxicity.
  • a modified B lymphocyte cell or cell line produces one or more antibodies and has one or more B cell receptors (membrane immunoglobulins as described herein) that are specific to target antigens, such as tumor antigens (including but not limited to, antigens that are mutant forms of“normal” cellular antigens, as well as antigens that are modified by way of post- translational modifications, and antigens that are expressed in an abnormal way or in an abnormal level).
  • a modified B lymphocyte cell or cell line is capable of mounting a complete immune response with both humoral as well as cellular immune components.
  • a modified B lymphocyte that exhibits cytotoxicity is competent to express (directly or indirectly) at least one of perforin, granzymes, and other cytotoxic components.
  • the B cell receptor membrane bound immunoglobulin
  • the modified lymphocyte is competent to secrete an antibody that is cytotoxic (e.g., by way of fixing complement or engaging ADCC [antibody-dependent cell-mediated cytotoxicity]) for the same tumor cell(s).
  • a modified B lymphocyte cell is derived from B cells following vaccination with tumor antigens, for example, or from donor peripheral blood
  • lymphocytes by modification of expression of at least one of antibody or B cell receptor (e.g., chimeric B cell receptor or recombinant B cell receptor).
  • B cell receptor e.g., chimeric B cell receptor or recombinant B cell receptor
  • a modified B lymphocyte cell is modified to express cytotoxicity by way of expression of a recombinant B cell receptor or a chimeric receptor with scFv and membrane immunoglobulin for extracellular transmembrane and cytoplasmic domains along with a cytoplasmic domain from IL21 receptor and TLR or another signaling molecule to elicit expression of granzyme, perforin, etc. from the modified B lymphocyte cell.
  • the modified B lymphocyte cell in the case of HIV infection, is able to mount a humoral as well as cytotoxic immune reaction.
  • the modified B lymphocyte cell can secrete neutralizing antibody for HIV particles or virally-infected cells.
  • the modified B lymphocyte cell in addition to the neutralizing antibody, can directly induce apopotosis or otherwise directly kill HIV infected cells (e.g. infected T cells in the lymph nodes, known as“reservoirs” of infected T cells not destroyed under current HIV anti-viral therapies.
  • the modified B lymphocyte cell can target auto-immune cells (e.g. multiple sclerosis cells, arthritis cells, etc.) that can be identified as self-reactive.
  • auto-immune cells e.g. multiple sclerosis cells, arthritis cells, etc.
  • the modified B lymphocyte cell induces apoptosis or otherwise directly kills such self-reactive cells.
  • these self-reactive cells include at least one of B cells, T cells, macrophages, or other immune cells.
  • these self- reactive cells include inflammatory cells
  • a modified B lymphocyte cell is modified to express a recombinant B cell receptor or chimeric B cell receptor specific for a first antigen and an antibody recognizing a second antigen, providing increased specificity as well as increased cellular cytotoxicity and antibody-mediated killing of the target cells (e.g. tumor cells, auto-immune cells, infected cells, inflammatory cells, necrotic cells, regulatory cells (e.g., regulatory T cells, regulatory B cells and myeloid-derived suppressor cells).
  • target cells e.g. tumor cells, auto-immune cells, infected cells, inflammatory cells, necrotic cells, regulatory cells (e.g., regulatory T cells, regulatory B cells and myeloid-derived suppressor cells).
  • a modified B lymphocyte cell with chimeric B cell receptor or recombinant B cell receptor has been modified to specifically react to one or more target cells, and exhibit cytotoxicity for the one or more target cells.
  • the modified B lymphocyte cell or cell line is engineered specifically for reaction with one or more tumor cells or tumor cell types.
  • the modified B lymphocyte cell or cell line is engineered through laboratory techniques and optionally through use of computer data and/or modeling of various components of the B lymphocytes.
  • the modified B lymphocyte cell with a chimeric B cell receptor or recombinant B cell receptor includes a modified receptor that is competent to transduce signals that induce expression of cytotoxic effector molecules, when the receptor is engaged.
  • the recombinant B cell receptor or chimeric B cell receptor includes a heterologous extracellular, trans-membrane and cytoplasmic signaling domain(s) that elicit expression of cytotoxic effector molecules.
  • the recombinant B cell receptor or chimeric B cell receptor includes a cytoplasmic domain derived from at least one of the common gamma chain, IL- 21R, a Toll-like receptor (TLR) or CD40.
  • the recombinant B cell receptor or chimeric B cell receptor is competent to elicit expression of cytotoxic effector molecules, such as perforin, granzyme B, Fas ligand, TRAIL, or others.
  • cytotoxic effector molecules such as perforin, granzyme B, Fas ligand, TRAIL, or others.
  • the recombinant B cell receptor or chimeric B cell receptor is competent to elicit expression of a TNF family receptor in the target cell, such as TNFR1, Fas receptor, DR4, DR5, or other“death domain” receptor.
  • the modified B cell secretes or expresses at least one of TNF- alpha ligand, lymphotoxin alpha or beta, OX40L, CD154, LIGHT, TL1-A, CD70, Siva, CD153, 4-1BB, RANKL, TWEAK, APRIL, BAFF, CAMLG, NGF, BDNF, NT-3, NT-4, GITR, TL1A, or EDA-A2.
  • CD 153 For example, expression of CD 153 on B cells in the presence of B cell receptor engagement and IL-4, results in Ig class switching, while CD 154 expression contributes to CD153 expression. See Cerutti, et al., J Immunol 2000 July 15; l65(2):786-794, which is incorporated herein by reference.
  • the CD 153“switch” for expression of alternate or additional genes or expression cassettes can be built into the modified B cells described herein.
  • OX40-OX40L interactions have been found to play a role in the development of several different inflammatory and autoimmune diseases, and which may be targeted for intervention. See for example, Croft, et al., Immunol Rev 2009 May,
  • the recombinant B cell receptor or chimeric B cell receptor includes at least one extracellular domain specific for one or more target antigens.
  • the recombinant B cell receptor or chimeric B cell receptor includes a modified receptor that recognizes a first antigen, and secretes an antibody that recognizes a second antigen.
  • the recombinant B cell receptor or chimeric B cell receptor includes a modified receptor that recognizes a first epitope of one antigen and secretes an antibody that recognizes a second epitope of the same antigen.
  • the modified B cells (with recombinant B cell receptor or chimeric B cell receptor) can be designed and engineered by laboratory techniques to be responsive to tumor cells with greater specificity and greater cytotoxic activity.
  • the modified B cells that exhibit cytotoxicity are further included in embodiments of B cells described herein that exhibit a chimeric B cell receptor or recombinant B cell receptor specific for one antigen and secrete antibodies specific for a different antigen than its B cell receptor.
  • Such memory B cells can also include the targeted cytotoxicity characteristics as described herein.
  • the target cells include cells that have been infected by virus, mycoplasma, bacteria, yeast, or other microorganism.
  • the target cells include tumor cells, such as primary tumor cells, circulating tumor cells, or metastatic tumor cells.
  • the target cells include auto-immune cells.
  • a method of making the modified B lymphocyte cells includes engineering cells by way of laboratory techniques. In an embodiment, a method of using the modified B lymphocytes for treatment of disease includes administering a
  • modified B lymphocyte cells therapeutically effective amount of the modified B lymphocyte cells to a subject.
  • Specific examples of methods of making the modified B lymphocyte cells are described in greater detail in the Prophetic Examples section herein.
  • a modified B lymphocyte cell or cell line as described herein is engineered, and utilized for administration to a subject for treatment.
  • the subject has active disease.
  • the subject has chronic disease.
  • the subject has been exposed to a disease-causing agent and may or may not yet have symptoms of disease.
  • the subject has latent disease.
  • a method for producing an immunoglobulin in a recombinant B lymphocyte cell line includes isolating from a vertebrate subject exposed to, e.g ., by infection, or immunized with at least one first antigen, a B lymphocyte cell line expressing at least one endogenous membrane immunoglobulin reactive to the at least one first antigen;
  • the isolated B lymphocyte cell line at least one exogenous nucleic acid encoding at least one of a secreted immunoglobulin reactive to at least one second antigen to produce a recombinant B lymphocyte cell line; and assaying for presence of the at least one exogenous secreted immunoglobulin reactive to the at least one second antigen to select the recombinant B lymphocyte cell line.
  • a method for treating a disease in a vertebrate subject with an immunotherapeutic product includes isolating from a vertebrate subject exposed to, e.g. , by infection, or immunized with at least one first antigen, a B lymphocyte cell line expressing at least one endogenous membrane immunoglobulin reactive to the at least one first antigen;
  • the isolated B lymphocyte cell line at least one of at least one exogenous nucleic acid encoding at least one secreted immunoglobulin reactive to at least one second antigen; assaying for presence of at least one exogenous secreted immunoglobulin reactive to the at least one second antigen to select the recombinant B lymphocyte cell line for administration to the vertebrate subject.
  • the isolated B lymphocytes can be used for immunotherapy:
  • -Long-lived isolated B lymphocytes can be used for immune surveillance of chronic disease.
  • Isolated B lymphocytes having membrane immunoglobulin recognizing antigen can act as exceptional antigen presenting cells to present antigen to T lymphocytes.
  • influenza immune B lymphocytes can be transfected en masse with retroviral vectors.
  • one may immunize with a vaccine and transfect multiple isolated B lymphocytes, e.g., polyclonal B lymphocytes, recognizing different epitopes of the same antigen.
  • An isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen or capable of expressing at least one endogenous secreted immunoglobulin reactive to a first antigen can be developed by immunizing an individual with a model antigen, e.g. , dinitrophenol (DNP) or an influenza antigen, to elicit memory B cells with endogenous membrane immunoglobulin, e.g. , B cell receptors (BCR), reactive to the DNP model antigen or the influenza antigen and/or endogenous soluble immunoglobulin, e.g. , antibody reactive to the DNP antigen or the influenza antigen.
  • a model antigen e.g. , dinitrophenol (DNP) or an influenza antigen
  • BCR B cell receptors
  • An isolated B lymphocyte cell line capable of expressing at least one exogenous secreted immunoglobulin reactive to a broadly neutralizing influenza antigen can be developed by isolating human B cells from an individual who is immune to influenza virus infection and immortalizing the human B cells by infecting the isolated B cells with Epstein Barr virus (EBV).
  • Epstein Barr virus EBV
  • Methods to clone immunoglobulin heavy (H) chain and light (L) chain genes from the EBV-immortalized B lymphocyte cell line may be used. See e.g., Li.S. Patent No. 7,741,077 issued to Granch et al. on June 22, 2010 and Early et al., Proc. Natl. Acad. Sci.
  • the immunoglobulin genes encoding the H chain and L chain for a secreted anti-influenza antibody are cloned in plasmid targeting vectors to obtain targeted integration in the corresponding nonfunctional, germline Ig loci on chromosomes 14 and 2 respectively.
  • memory B cells obtained from a patient with a chronic viral infection can be genetically engineered by replacing their functional, expressed Ig genes with exogenous Ig genes encoding a membrane immunoglobulin, e.g ., anti-DNP antibody.
  • the Ig H and Ig L chain genes encoding the anti-DNP antibody may be inserted in the functional, expressed Ig gene loci on chromosomes 14 and 2 by using methods of homologous recombination. See e.g., U.S. Patent Nos. 5,202,238, 6,570,061, and 6,841,383.
  • Memory B cells expressing anti-DNP membrane IgG can be engineered to express Ig genes encoding a secreted IgG antibody specific for influenza.
  • the anti -influenza IgGi H chain gene i.e., gi-H chain gene
  • the anti -influenza IgGi H chain gene may be engineered to remove coding sequences for the membrane spanning domain (TM), the cytoplasmic amino acids (Cyt), and a polyA addition site to yield a gi-H chain gene encoding a secreted H chain only.
  • a hybridoma cell line that produces the anti- PSA antibody is constructed.
  • transgenic mice with human Ig genes e.g, XenoMouse® available from Abgenix Inc., Fremont, CA
  • a myeloma cell fusion partner e.g. SP2/0 cells (available from American Type Culture Collection, Manassas, VA) to create hybridoma cell clones expressing human antibodies (see e.g, U.S. Patent No. 8,013,128 Ibid).
  • Supernatants from the hybrid clones are screened using an immunoassay to detect human IgG antibodies which bind PSA protein.
  • Hybridoma clones producing antibodies that recognize PSA are expanded and antibodies from each clone are tested using a BiacoreTM A100 instrument (available from GE Healthcare, Piscataway, NJ) to measure antibody affinity and specificity for PSA (see e.g., GE Healthcare, Application Note 84,“Early kinetic screening of hybridomas.. which is incorporated herein by reference).
  • Hybridomas expressing high affinity antibodies for PSA are selected for cloning of their human Ig genes, for example, by homologous recombination.
  • the engineered immunoglobulin genes encoding a membrane immunoglobulin are expressed in a mammalian cell line and the membrane IgG is purified from the cell line.
  • a kappa (K) L chain gene and the modified g-l H chain gene are inserted in a lentiviral expression vector using standard recombinant DNA methods (see e.g., U.S. Patent Publication No. 2007/0116690 by Yang et al. published on May 24, 2007 which is incorporated herein by reference).
  • the viral vector is used to transfect Chinese Hamster Ovary (CHO) cells (available from American Type Culture Collection, Manassus, VA) which are engineered to express the membrane immunoglobulin.
  • a suicide gene may be introduced into the B cells.
  • a suicide gene herpes simplex virus- thymidine kinase gene (HSV-TK) is introduced using a retroviral expression vector.
  • HSV-TK herpes simplex virus- thymidine kinase gene
  • B cells expressing HSV-TK are provided with 20 mM ganciclovir (available as Cytovene IV from Roche Laboratories, Nutley, NJ). Conversion of ganciclovir into a toxic metabolite by the B cells expressing HSV-TK results in their death. Cells not expressing HSV-TK are not harmed by ganciclovir.
  • CID chemical inducers of dimerization
  • a proapototic molecule is adapted to encompass one or more binding sites for a CID, which once reaching its target(s) causes their oligomerization with ensuing activation of the apoptotic pathway.
  • different apoptotic pathways can operate as suicide systems, including the death receptor Fas and the enzyme Caspase 9. Beside a very low risk for immunogenicity, these suicide genes share the advantages of non cell-cycle dependency, full clinical compatibility and optimal biodistribution, as CID are small molecule vibrantly designed for suicide purposes. See , for example, J Cancer. 2011; 2: 378-382, which is incorporated herein by reference.
  • the isolated cell line can include an isolated B lymphocyte cell line or an isolated recombinant B lymphocyte cell line that recognizes one or more antigens to an infectious bacterial or viral disease, e.g. , influenza antigen.
  • Table 1 includes examples of protocols for constructing the isolated B lymphocyte cell line or the isolated recombinant B lymphocyte cell lines including an exogenously-derived and/or endogenously-derived membrane immunoglobulin and exogenously-derived and/or endogenously-derived secreted immunoglobulin.
  • the secreted immunoglobulin from the isolated recombinant B lymphocyte cell line can include one or more secreted anti-influenza broadly neutralizing antibodies (Flu BNAb).
  • the anti-influenza broadly neutralizing antibodies can be directed to two or more epitopes on the same influenza antigen (Flu BNAbl and Flu BNAb2).
  • the secreted anti-influenza immunoglobulin from the isolated recombinant B lymphocyte cell line can include one or more secreted polyclonal antibodies (Flu Ab n ) to the influenza 5 antigen.
  • B lymphocyte protocol l is a protocol to produce isolated recombinant B lymphocytes.
  • the protocol 1 immunizes a vertebrate subject with DNP-KLH
  • BNAb neurotrophenyl -Keyhole Limpet Hemocyanin
  • select memory B lymphocytes including membrane immunoglobulin recognizing DNP and secreted immunoglobulin recognizing DNP.
  • Anti-DNP B lymphocytes can be transfected with nucleic acid vector including immunoglobulin genes encoding membrane and secreted anti -influenza broadly neutralizing antibody (BNAb).
  • the isolated recombinant anti -influenza B lymphocytes can be transferred to a vertebrate subject to protect the vertebrate subject from influenza infection.
  • the long- lived anti -influenza B lymphocytes can be activated at will by injecting DNP-KLH into the vertebrate subject when flu symptoms arise or when a pandemic hits.
  • B lymphocyte protocol 2 is a protocol to produce isolated recombinant B
  • the protocol 2 isolates memory B lymphocytes from a vertebrate subject.
  • the isolated memory B lymphocytes are transfected with a nucleic acid vector including immunoglobulin genes encoding anti-DNP membrane immunoglobulin only and not anti- DNP secreted immunoglobulin.
  • B lymphocytes with anti-DNP membrane immunoglobulin can be selected and transfected with immunoglobulin genes encoding two anti- influenza BNAbs to two different epitopes of the influenza antigen.
  • the immunoglobulin genes encoding each BNAb can encode membrane and secreted forms of the BNAbs.
  • the isolated recombinant anti -influenza B lymphocytes can be transferred to a vertebrate subject to protect the vertebrate subject from influenza infection.
  • the long- lived anti -influenza B lymphocytes can be activated at will to produce two anti- influenza BNAbs by injecting DNP-KLH into the vertebrate subject when flu symptoms arise or when a pandemic hits.
  • the long-lived anti-influenza B lymphocytes can also be activated at will to produce two anti- influenza BNAbs by injecting influenza antigen into the vertebrate subject.
  • no secreted immunoglobulin to DNP-KLH will be produced when the B lymphocytes are activated by DNP-KLH or by influenza antigen.
  • B lymphocyte protocol 3 is a protocol to produce polyclonal isolated recombinant B lymphocytes.
  • the protocol 3 immunizes a vertebrate subject with influenza vaccine, e.g ., tripartite seasonal influenza vaccine.
  • Memory B lymphocytes that express membrane immunoglobulin recognizing the influenza vaccine antigens are selected in the vertebrate subject.
  • the selected polyclonal anti- influenza memory B lymphocytes are transfected with immunoglobulin genes encoding an anti-DNP membrane immunoglobulin.
  • the polyclonal anti -influenza B lymphocytes can be transferred to a vertebrate subject to protect the vertebrate subject from influenza infection.
  • the polyclonal, long- lived anti -flu B cells can be activated en mass by injecting DNP-KLH into the vertebrate subject when flu symptoms arise or when a pandemic hits.
  • individual B lymphocyte clones can be activated by their cognate influenza antigen.
  • B lymphocyte protocol 4 is a protocol to produce polyclonal isolated recombinant B lymphocytes.
  • the protocol 4 immunizes a vertebrate subject with influenza vaccine, e.g. , tripartite seasonal vaccine.
  • Memory B lymphocytes that express membrane immunoglobulin recognizing the influenza vaccine antigens are selected in the vertebrate subject.
  • Polyclonal anti- influenza B lymphocytes are transfected with immunoglobulin genes encoding anti -influenza BNAb in both membrane form and secreted form.
  • the isolated recombinant polyclonal anti -influenza B lymphocytes can be transferred to a vertebrate subject to protect the vertebrate subject from influenza infection.
  • the polyclonal, long-lived anti- influenza B lymphocytes can be activated en mass by injecting a full spectrum of influenza vaccine antigens into the vertebrate subject when flu symptoms arise or when a pandemic hits.
  • Each B lymphocyte produces a BNAb and a clone -specific immunoglobulin reactive with influenza.
  • the isolated B lymphocyte cell line including at least one exogenously incorporated membrane immunoglobulin activated by the first antigen is capable of controlling expression of the at least one endogenous secreted immunoglobulin reactive to the second antigen.
  • the exogenously incorporated membrane immunoglobulin acts as a receptor to a specified ligand, e.g ., the first antigen. Binding of the first antigen to the exogenously incorporated membrane immunoglobulin controls signal transduction through the exogenously incorporated membrane immunoglobulin to control expression from the at least one endogenous secreted immunoglobulin reactive to the second antigen. Binding of the first antigen to the exogenously incorporated membrane immunoglobulin controls signal transduction through the membrane immunoglobulin to control activation of the B lymphocyte or differentiation of the B lymphocyte.
  • Figure 1 is a schematic of a diagrammatic view of hypothetical immunoglobulin genes for memory B lymphocytes.
  • Heavy (H) chain gene is on chromosome 14.
  • Kappa (K) L chain gene is on chromosome 2.
  • Lambda (l) L chain gene is on chromosome 22. A functional allele and a nonfunctional allele are present on chromosomes 14 and 2. Both l L chain alleles are depicted as nonfunctional.
  • Example 3 the
  • immunoglobulin genes encoding the H chain and L chain for an anti-PSA membrane antibody are cloned in targeting plasmid vectors to allow targeted integration in the corresponding nonfunctional Ig loci on chromosomes 14 and 2 respectively.
  • FIGs 2A, 2B, and 2C are a schematic of a diagrammatic view of nonfunctional and functional immunoglobulin heavy chain genes on chromosomes 14.
  • the genetic structure of maternal chromosome 14 germline configuration is shown in Figure 2A. Exons for variable regions (V H ), D segments (D), J segments (J H ), IgM constant region (CHP), secreted tailpiece (TP) and the m membrane anchor (TM and Cyt) are shown in Figure 2B.
  • the genetic structure of paternal chromosome 14 functionally rearranged is shown with recombined V, D and J segments (V H D I J 2 ) as shown in Figure 2C.
  • Ig gene structure is simplified with only one constant region (CH) exon shown. Also promoter and enhancer sequences are omitted.
  • the anti-PCLA immunoglobulin H and L chain genes are integrated into the Ig loci of the mature B cell which are functionally rearranged on chromosomes 14 and 2 respectively. See Fig. 2B for functionally rearranged H chain locus.
  • Figures 3A, 3B, and 3C are a schematic of a diagrammatic view of replacement of immunoglobulin genes with heavy chain genes engineered to express membrane IgG and secreted IgG.
  • the genetic structure of secreted and membrane g-H chain gene with alternate polyadenylation sites are shown in Figure 3 A.
  • the genetic structure of maternal chromosome 14 with an engineered membrane g-H chain gene is shown in Figure 3B.
  • the genetic structure of paternal chromosome 14 with an engineered secreted g-H chain gene is shown in Figure 3C. Note that Ig gene structure is simplified with only one constant region (CH) exon shown. Also promoter and enhancer sequences are omitted.
  • CH constant region
  • the anti-PCLA IgG H chain gene (i.e., g-H chain gene) may be engineered to remove coding sequences for the membrane spanning domain (TM) and the cytoplasmic amino acids (Cyt) to yield a g-H chain gene encoding a secreted H chain only (Fig. 3C).
  • Figures 4A, 4B, 4C, 4D are a schematic of a diagrammatic view of protocols to produce recombinant B lymphocytes with membrane immunoglobulin to a first antigen and secreted immunoglobulin to a second antigen.
  • Figure 4A shows isolated memory B lymphocytes with endogenous DNA encoding anti-DNP membrane immunoglobulin and exogenous DNA encoding anti-Flu broadly neutralizing antibody (BNAb) secreted immunoglobulin.
  • Figure 4B shows isolated memory B lymphocytes with exogenous DNA encoding anti-DNP membrane immunoglobulin and exogenous DNA encoding anti-Flu broadly neutralizing antibody (BNAb) secreted immunoglobulin.
  • Figure 4C shows isolated memory B lymphocytes with endogenous DNA encoding anti-Flu Abs secreted immunoglobulin and exogenous DNA encoding anti-DNP membrane immunoglobulin.
  • Figure 4D shows isolated memory B lymphocytes with exogenous DNA encoding an anti- Flu BNAb secreted immunoglobulin and exogenous anti-DNP membrane immunoglobulin polypeptide delivered with liposomes.
  • Figure 5 is a schematic of a diagrammatic view of a method 500 for producing at least one immunoglobulin in an isolated B lymphocyte cell line 501 that includes isolating 502 from a vertebrate subject immunized with at least one second antigen, a B lymphocyte cell expressing at least one endogenous secreted immunoglobulin reactive to the at least one second antigen; introducing 503 into the isolated B lymphocyte cell at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce a recombinant B lymphocyte cell line; expanding and selecting 504 the isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen and expressing the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen.
  • Figure 6 is a schematic of a diagrammatic view of a method 600 for producing at least one immunoglobulin in an isolated B lymphocyte cell line 601 that includes introducing 602 into at least one isolated B lymphocyte cell at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce at least one first isolated B lymphocyte cell line; expanding and selecting 603 the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen; introducing 604 into the at least one first isolated B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted
  • Figure 7 is a schematic of a diagrammatic view of a method 700 for producing at least one immunoglobulin in a recombinant B lymphocyte cell line 701 that includes isolating 702 from a vertebrate subject immunized with at least one first antigen, a B lymphocyte cell expressing at least one endogenous membrane immunoglobulin reactive to the at least one first antigen; introducing 703 into the isolated B lymphocyte cell at least one exogenous nucleic acid encoding at least one of a secreted immunoglobulin reactive to at least one second antigen and expand the cell to produce a recombinant B lymphocyte cell line; and assaying 704 for presence of the at least one exogenous secreted immunoglobulin reactive to the at least one second antigen to select the recombinant B lymphocyte cell line.
  • Figure 8 A illustrates a recombinant B cell receptor protein 1000 with a single- chain variable fragment 1005 joined to IgG heavy chain domains that include a hinge segment 1008, joined to CH3 domain 1010, transmembrane 1015, and cytoplasmic 1020 domains attached to an IL-21 receptor cytoplasmic domain 1025.
  • Figure 8B includes an illustration of a recombinant B cell receptor expression vector 1055 that includes a CMV promoter 1028 joined to a recombinant B cell receptor 1030 attached to a poly- A site 1035 and a neomycin resistance gene 1040.
  • Figure 8C is an illustration of an active gamma heavy chain locus on chromosome 14 with perforin gene inserted 1105, including an Ig variable gene promoter 1045 joined to perforin cDNA 1048 and downstream an Ig alpha constant region 1049, with transmembrane domain 1051 and cytoplasmic domain 1052.
  • Figure 8D includes an illustration of a Sendai virus expression vector with transcription factor genes inserted 1150 including a viral NP gene 1065 joined to a viral P/V gene 1062, with three transcription factors T-bet 1064, RunX3 1066, and Eomes 1068 with the viral L gene 1075 at the 3 -prime end.
  • Figure 9A illustrates the integration of a single chain (SC) antibody gene at the active, rearranged kappa light chain locus on human chromosome 2.
  • PCLA single chain
  • HA homology arms
  • Figure 9B shows the targeted integration of a chemokine receptor gene (CXCR3) at the active, rearranged immunoglobulin (Ig) mu heavy-chain locus.
  • CXCR3 chemokine receptor gene
  • Ig immunoglobulin
  • the edited Ig mu heavy chain gene on chromosome 14 is shown.
  • Figure 10 illustrates a method 1000 of activating the modified B cell 1070 engineered with a predetermined exogenous or endogenous membrane immunoglobulin 1060 to selectively engage a first target antigen 1050 and subsequently secrete a predetermined antibody 1080 to a second target antigen 1220 and/or secrete a reassigned biological agent and/or cytotoxic effector molecule(s) (1310) resulting in the death of target cell(s) 1210.
  • the modified B cell includes engaging or allowing to engage 1100 an antigen (either engineered or naturally occurring) with the predetermined surface immunoglobulin 1060.
  • receptor engagement 1100 leads to secretion of the predetermined (exogenously or endogenously incorporated) antibody 1080 configured to engage with the second target antigen 1220 on the target cell 1210.
  • the next step 1300 includes the optional secretion of one or more cytotoxic molecules (which may be reassigned biological agents) 1310 for additional target cell destruction.
  • Figure 11 illustrates a lymph node 1111 with modified B cells 1117 that recognize particular target antigens 1118 that contribute to activation of the modified B cells.
  • the medulla 1115 is rich in macrophages and plasma cells, while the cortex 1114 contains mostly inactivated B and T cells, as well as dendritic cells and macrophages.
  • the modified B cells are implanted into the lymph node 1111 for example, in the cortical area 1114 to be activated, or even if they are already activated.
  • the afferent lymph vessel 1113 and efferent lymph vessel 1112 brings immune system cells into and out of the lymph node 1111.
  • the germinal centers 1116 include locations for mature B cells to proliferate, differentiate, and generate antibody.
  • the modified B cells can be implanted into one or more germinal centers 1116 of the subject’s lymph node 1111.
  • a B cell stimulation device 1205 can be implanted, for example in the cortical area or capsular space of the lymph node 1111.
  • the B cell stimulation device 1205 can include an array of wells 1208 which can include, for example, different antigens and/or different concentrations of antigens and/or different adjuvants and/or different concentrations of adjuvants.
  • wells 1208 can include, for example, different antigens and/or different concentrations of antigens and/or different adjuvants and/or different concentrations of adjuvants.
  • a predetermined antigen 1207 is remotely triggered to be released in the lymph node and eventually the predetermined antigen 1118 reaches the modified B cells 1117 for engagement.
  • Such engagement can include priming (or being a“booster”) of the modified B cells, or can be an initial activation of the modified B cells, or if desired, can be a tolerizing of the modified B cells (for example, with“self-antigen” related to an autoimmune disease).
  • the B cell stimulation device 1205 can include remotely triggering different antigens and/or concentrations over time 1119 and can act on naturally occurring B cells as well as modified B cells described herein. For example, over time 1119 the B cell stimulation device 1205 can release three different concentrations and/or antigens into the blood stream or lymph node.
  • Figure 12A illustrates insertion of a gene for interleukin 10 (IL-10) at the first exon of the active, rearranged Ig heavy chain gene on chromosome 14.
  • IL-10 interleukin 10
  • V H DJ variable region
  • CipA poly A addition site
  • HA flanking homology arms
  • Figure 12B shows a lenti viral expression vector encoding a single chain membrane antibody specific for an autoantigen, myelin oligodendrocyte glycoprotein (MOG).
  • the vector contains a cytomegalovirus promoter element (CMV) directing transcription of the single chain antibody.
  • CMV cytomegalovirus promoter element
  • the single chain antibody includes a single chain Fv (SCFV) segment fused to an Ig gamma constant region gene.
  • Figure 13 illustrates integration of a bicistronic construct downstream (3’) of the VH promoter and mu enhancer (pEnh) leading to disruption of the active rearranged Ig gamma heavy chain gene on chromosome 14.
  • the location of guide RNAs (gRNA) to target CRISPR-mediated integration in the intron and yCH l exon of the gamma heavy chain gene are indicated.
  • the class switch recombination site (CSRS) is indicated.
  • An AAV vector encoding a bicistronic construct is illustrated.
  • the bicistronic construct includes genes for a recombinant B cell receptor (recBCR) and interleukin 21 (IL-21) with self-cleaving peptides (P2a) encoded before each gene.
  • the edited gamma heavy chain gene is shown with the bicistronic construct expressed under the control of the VH promoter and mu enhancer. Expression of the gamma H-chain gene is disrupted by the bic
  • the recombinant B lymphocyte cell line may be autologous to one of the one or more vertebrate subjects.
  • the recombinant B lymphocyte cell line may be allogeneic to one of the one or more vertebrate subjects. In the case where the recombinant B lymphocyte cell line is allogeneic to one of the one or more vertebrate subjects.
  • the recombinant B lymphocyte cell line can be modified to reduce or eliminate expression of MHC Class I (MHC I) proteins or mismatched ELLA antigens in the recombinant B lymphocyte cell line to avoid allograft rejection and to reduce or eliminate a graft versus host disease in the recipient of the allogeneic recombinant B lymphocyte cells.
  • MHC I MHC Class I
  • ELLA antigens in the recombinant B lymphocyte cell line to avoid allograft rejection and to reduce or eliminate a graft versus host disease in the recipient of the allogeneic recombinant B lymphocyte cells.
  • a vertebrate subject is treated with unmatched, allogeneic donor recombinant B lymphocyte cells engineered to block the presentation of Major Histocompatibility Class I (MHC I) proteins on their cell surface.
  • Allogeneic donor recombinant B lymphocyte cells are transfected with a lentiviral expression vector that directs the expression of a microRNA (miRNA) that inhibits beta2 -microglobulin (b 2 M) protein translation and blocks MHC I assembly and presentation on the cell surface.
  • miRNA microRNA
  • b 2 M beta2 -microglobulin
  • the genetically engineered recombinant B lymphocyte cells are injected into the patient.
  • the inhibition of MHC I production in engrafted recombinant B lymphocyte cells is controlled by a regulatory module and an effector molecule, doxycycline.
  • doxycycline is administered to repress expression of the miRNA, thereby allowing expression of b 2 M and MHC I on the cell surface and evoking an alloreactive immune response.
  • a vertebrate subject is treated with recombinant B lymphocyte cells that have reduced expression of Major Histocompatibility Class I (MHC I) proteins on their cell surface, in order to avoid immune rejection of the transplanted cells.
  • the engineered recombinant B lymphocyte cells also contain a suicide mechanism that can be activated by the administration of a prodrug, ganciclovir, in the event of uncontrolled proliferation or other adverse events associated with the recombinant B lymphocyte cells.
  • a vertebrate subject is treated with a recombinant B lymphocyte cells that are modified to reduce their expression of mismatched HLA antigens and thus avoid allograft rejection.
  • Recombinant B lymphocyte cells are infected with a lentivirus vector encoding microRNA (miRNA) that inhibits the expression of specific donor HLA alleles not shared by the recipient.
  • miRNA microRNA
  • Production of mismatched HLA- A, -B, -C, -DRBI, and -DQB1 alleles are blocked by miRNAs, and the corresponding HLA proteins are not expressed by the modified donor recombinant B lymphocyte cells.
  • a vertebrate subject is treated by transplantation with recombinant B lymphocyte cells.
  • Allogeneic recombinant B lymphocyte cells are modified to reduce expression of MHC Class I (MHC I) proteins by expression of a viral gene that targets MHC I proteins for destruction.
  • Recombinant B lymphocyte cells are transduced with a lentiviral expression vector encoding cytomegalovirus (CMV) protein, unique sequence 11 (US11), to target MHC I proteins for destruction and avoid allograft rejection (see e.g ., Lin et al ., Cellular and Molecular Immunology 4: 91-98, (2007), which is incorporated herein by reference).
  • CMV cytomegalovirus
  • the one or more modified B lymphocyte cells have been engineered to secrete a non-antibody protein (e.g., glycoprotein, proteoglycan, amino acid, etc.) when prompted by engagement with the surface immunoglobulin with a specifically designed“trigger” antigen.
  • a non-antibody protein e.g., glycoprotein, proteoglycan, amino acid, etc.
  • the non-antibody protein may include a neurotransmitter, hormone, cytokine, fat, vitamin, mineral, or anti-inflammatory agent.
  • one or more neurotransmitters such as dopamine, serotonin, acetylcholine, GABA, norepinephrine, oxytocin, etc., are secreted by the modified B lymphocyte cells.
  • one or more neurotransmitters are secreted by one or more modified B lymphocyte cells upon ingestion, injection, implantation, or otherwise a transfer of the modified B lymphocytes to a subject.
  • modified B lymphocyte cells upon ingestion, injection, implantation, or otherwise a transfer of the modified B lymphocytes to a subject.
  • naturally occurring B lymphocytes will home to Peyer’ s patches and other areas of the gastrointestinal tract upon oral ingestion (e.g., by way of breastmilk). See, for example, Cabinian et al, PLoS One. 2016; 11(6): e0l56762, which is incorporated herein by reference.
  • microbiome plays a role in cancer development, progression, and therapy. See , for example, Bhatt et al, CA Cancer J Clin 20l7;67:326- 344, which is incorporated herein by reference.
  • an oral or other formulation of a composition including one or more modified B lymphocytes as described herein can be provided to a subject for treatment of a disease or indication.
  • a composition can be delivered in another route, for example as an intramuscular injection, subcutaneous injection, sublingual administration, buccal administration, parenteral administration, anal administration, intralymphatic administration, or another route of administration that is sufficient to provide delivery of the composition to the subject for treatment.
  • an oral or other formulations of composition including one or more modified B lymphocytes further includes one or more life, dead, or preserved strains of microorganism, such as E. coli, Bacteroides, Bifidobacterium, Bacillus,
  • Saccharomyces Prevotella tanneraie, Neisseria lactamica, Streptococcus,
  • the modified B cells provide surveillance in the subject’s body, such that the cells are directed to secrete a specific antigen when the cell’s surface immunoglobulin receptor is triggered with the antigen selected for in the process of engineering the cells.
  • a particular antigen e.g., DNP-KLH
  • DNP-KLH a particular antigen
  • the endogenous response of these modified B cells should be limited to stimulation without over- stimulation that could result in tolerance to the antigen rather than antibody secretion reaction. Further, a DNP conjugate of a peptide from KLH would likely elicit a restricted endogenous response.
  • the modified B cells are stimulated or restimulated to use an alternate carrier (e.g., DNP -Human Serum Albumin) which should not elicit an immune response but will provide a“booster” antigen stimulation to the modified B cells.
  • an alternate carrier e.g., DNP -Human Serum Albumin
  • a B cell stimulation device is implanted in or on the subject in order to provide stimulation or re-stimulation of the modified B cells (or of a patient’s own innate B cells).
  • the B cell stimulation device can include a microarray or microchip device with antigen (and optionally adjuvant, cytokines, chemokines, etc.) on or in the device and can be injected into a subject such that activating the antigen-carrying device allows for release of the antigen and/or adjuvant for“boosting” the activation of the modified B cells.
  • a microchip containing one or more small, hermetically sealed compartments can be activated by remote control (eg wireless signal) to trigger the release of one or more compartments.
  • the one or more compartments can be triggered to release the antigen and/or adjuvant and/or other molecules (eg cytokines, chemokines, growth factors, etc.) based on a pre-programmed dosing schedule.
  • the one or more compartments can be triggered as desired.
  • the subject can control the trigger for the B cell stimulation device.
  • another entity can control the trigger for the subject’s B cell stimulation device.
  • the B cell stimulation device is placed in lymphatic tissue of a subject, including but not limited to, for example, lymph nodes, GALT, MALT, spleen, liver, etc. See Figure 11.
  • the B cell stimulation device can be easily implanted and/or removed in a healthcare setting.
  • the B cell stimulation device can include at least ten, at least twenty, at least fifty, at least one hundred, at least two hundred, or more doses for stimulating B cells.
  • each dose is the same in a particular B cell stimulation device.
  • multiple different doses include different contents (eg different antigen and/or different adjuvant).
  • the compartments of the B cell stimulation device is configured such that each dose can be released at a specific time (eg by pre-determined program, by way of sensors detecting a specific physiological parameter that causes or warrants release of a dose, or by active intervention by the subject or another entity such as a healthcare worker or computing device).
  • the B cell stimulation device includes multiple different antigens and/or multiple different adjuvants and/or cytokines or other molecules such as ligands or transcription factors (configured as each in its own compartment or a mix of two or more in a single compartment) and can be wirelessly released into the subject’s body.
  • each compartment is independently addressable and
  • the B cell stimulation device includes electronic circuitry including wireless communications (eg radio frequency), circuitry in electronic communication with each compartment for independent release of its contents, timer or clock for accurate interval spacing and/or release of contents of a compartment, and a controller in electronic communication with the various electrical components for proper functioning.
  • wireless communications eg radio frequency
  • circuitry in electronic communication with each compartment for independent release of its contents
  • timer or clock for accurate interval spacing and/or release of contents of a compartment
  • a controller in electronic communication with the various electrical components for proper functioning.
  • a wirelessly controlled implantable microchip-based drug delivery device for delivering human parathyroid hormone fragment has been successfully tested in clinical trials in humans as a bioequivalent to daily injections. See , for example, Farra, Science Translational Med 22 Feb 2012, Vol. 4, Issue 122, pp. l22ra2l, which is incorporated herein by reference.
  • a B cell stimulation device similar to the microchip device described in the citation above is configured for stimulating B cells in a subject, including the modified B cells described herein throughout.
  • a microchip array device with discrete compartments with an impermeable, thin metallic membrane is configured to retain the contents in a lyophilized form or other activatable form.
  • the metallic membrane can be removed by electrothermal ablation, which releases the contents of the compartment in a controlled manner.
  • a B cell stimulation device is inserted subcutaneously into a subject that has already received or will receive modified B cells as described herein.
  • the B cell stimulation device is implanted into a lymphoid tissue of a subject that has already received or will receive modified B cells as described. Lymphoid tissue can include, for example, lymph nodes, tonsils, spleen, Peyer’s patches, mucosa associated lymphoid tissue, bone marrow, or thymus.
  • a B cell stimulation device can be approximately 50 mm x 30 mm x 10 mm (1 x w x h), as described in Farra herein above, with two microchips with 10 reservoirs each. In an embodiment, the stimulation device can be approximately half this size, with a single microchip with 10 reservoirs each. In an embodiment, the stimulation device can be much smaller, for example, a single microchip with 1, 2, 3, 4, 5, 6, 7, 8, or 9 reservoirs.
  • the B cell stimulation device includes at least one compartment with an enzyme, such as collagenase, to assist with penetration of the fibrous membrane capsule that can form around any implant in a subject’s body.
  • an enzyme such as collagenase
  • the fibrous tissue capsule is less than one mm thick and allows for passage of molecules through it. Id.
  • enzymatic release prior to release of B cell stimulants can be performed.
  • one or more compartments containing collagenase or other enzymes are released prior to release of the B cell stimulants (eg antigen, adjuvant, cytokine, other immune stimulant, etc.).
  • the modified B cells described herein are stimulated or re- stimulated by physical biopsy sampling of suspected tumor tissue, or lymph node.
  • BCR B cell receptor
  • DNP-KLH dinitrophenol-keyhole limpet hemocyanin
  • a secreted antibody that neutralizes multiple strains of influenza virus.
  • An isolated recombinant B lymphocyte cell line that produces a secreted broadly neutralizing immunoglobulin to influenza virus and produces a membrane
  • immunoglobulin to a model antigen can be utilized for cell therapy in a mammalian subject.
  • the recombinant B lymphocyte cell line can be injected into the mammalian subject as cell therapy to provide immunological protection from infection by influenza virus.
  • the recombinant B lymphocyte cell line can be activated in vivo or ex vivo to produce the broadly neutralizing influenza antibody by injecting the mammalian subject (or an in vitro cell culture) with model antigen, dinitrophenol-keyhole limpet hemocyanin (DNP-KLM).
  • DNP-KLM dinitrophenol-keyhole limpet hemocyanin
  • the timing to stimulate immunological protection from influenza virus infection in the mammalian subject can be chosen based upon the timing of an outbreak of influenza infection in the population at large.
  • DNP dinitrophenol
  • BCR B cell receptors
  • Memory B cells develop in response to immunization with DNP conjugated to a carrier protein, keyhole limpet hemocyanin (KLH).
  • KLH keyhole limpet hemocyanin
  • a primary immunization with 1 mg of DNP- KLH is injected subcutaneously in the right arm. See e.g. , Rentenaar et ah, Kidney International 62: 319-328, 2002 which is incorporated herein by reference.
  • DNP-HSA-biotin dinitrophenol -human serum albumin-biotin
  • phycoerythrin-streptavidin available from Biosearch
  • DNP-specific memory B cells are isolated by cell sorting with a fluorescence activated cell sorter (e.g, FACSArialll® available from Becton Dickinson, Franklin Lakes, NJ).
  • a fluorescence activated cell sorter e.g, FACSArialll® available from Becton Dickinson, Franklin Lakes, NJ.
  • Memory B cells expressing BCRs that binds DNP are genetically engineered to express a secreted antibody which is a broadly neutralizing antibody reactive with multiple strains of influenza.
  • Memory B cells expressing anti-DNP BCRs, containing membrane IgG antibodies have a productively rearranged and expressed membrane immunoglobulin heavy (H) chain gene which resides on chromosome 14 (one of two parental chromosome 14 copies).
  • the other parental chromosome 14 has an immunoglobulin (Ig) H chain gene that is not productively rearranged and not expressed. See Figs. 1, 2A and 2B. This phenomenon, termed“allelic exclusion”, yields individual B cells which express only one Ig heavy chain (and one Ig light (L) chain) and thus only one antibody (see e.g.,
  • the memory B cells expressing anti-DNP BCRs are modified by replacing the non-functional, non-expressed immunoglobulin genes with functional, expressed immunoglobulin genes (for H and L chain).
  • the replacement immunoglobulin genes may encode a secreted antibody, which is a broadly neutralizing anti-influenza antibody.
  • the IgH chain or IgL chain chromosomal loci are non-expressed Ig alleles where, for example, the endogenous rearranged VH promoter proximal to the mu enhancer is utilized for expression (due to V-J joining, the non-expressed allele will likely not have a VH promoter proximal to the Constant region).
  • the immunoglobulin genes encoding a broadly neutralizing antibody reactive with multiple strains of influenza virus may be isolated from the chromosomal DNA of a human B cell clone that produces the antibody.
  • human B cells isolated from an individual who is immune to influenza virus infection are immortalized by infecting the isolated B cells with Epstein Barr virus (EBV).
  • EBV Epstein Barr virus
  • Supernatants derived from individual EBV-transformed B cell clones are tested in an immunoassay for antibodies that recognize influenza virus.
  • Methods to immortalize B cells and to detect anti-viral antibodies are described (see e.g., Zhang et al., Proc. Natl. Acad. Sci. USA 107: 732-737, 2010 and Corti et al., J. Clin. Investigation 120: 1663-1673, 2010 which are incorporated herein by reference).
  • Ig heavy chain and light (L) chain genes may be used. See e.g., Ei.S. Patent No. 7,741,077 issued to Granch et al. on June 22, 2010 and Early et al., Proc. Natl. Acad. Sci. USA 76: 857-861,1979 which are incorporated herein by reference.
  • an EBV-transformed B cell line expressing a human anti influenza antibody, IgGi(kappa) is grown in culture and used as a source to isolate messenger RNA (mRNA) and genomic DNA using standard methods employing phenol/chloroform.
  • mRNA messenger RNA
  • mRNA encoding the IgGi H chain and the kappa L chain are molecularly cloned following amplification using the polymerase chain reaction (PCR) and reverse transcriptase (RT).
  • PCR polymerase chain reaction
  • RT reverse transcriptase
  • the H and L chain mRNA (amplified as complementary DNA) are cloned in a plasmid vector (e.g ., pCR®2. l-TOPO plasmid available from Invitrogen Corp., Carlsbad, CA).
  • a plasmid vector e.g ., pCR®2.
  • l-TOPO plasmid available from Invitrogen Corp., Carlsbad, CA.
  • the DNA sequence of the Ig H chain variable (V) region (including the Vh, D and J segments) and the kappa L chain V-region (including the Vk and Jk segments) are determined.
  • the V-region DNA sequences may be determined by automated DNA sequencing (DNA sequencing services are available from Charles River Laboratories International, Inc., Wilmington, MA).
  • genomic DNA isolated from the anti-influenza B cell line is used as a template for PCR amplification of the human H chain gene and kappa L chain gene.
  • PCR primers oligonucleotides
  • V-region genes including their respective promoters and flanking regions upstream (i.e., 5’ of the V genes
  • searching a human genome database with the V- region DNA sequences established from the cloned Ig mRNA.
  • a human genome nucleotide database available from the National Center for Biotechnology
  • BLAST Human RefSeq Genome database and BLAST software are available online (see e.g., the world wide web at blast.ncbi.nlm.nih.gov/Blast.cgi). Primers to amplify the Ig constant regions, enhancer sequences, the H-chain membrane anchors, poly A addition sites and downstream flanking regions (i.e., 3’ of the Ig genes) are described (see e.g., U.S. Patent No. 7,741,077 Ibid ). The PCR-amplified, genomic fragments can be cloned in a plasmid vector such as pCR®2. l-TOPO available from Invitrogen Corp., Carlsbad, CA).
  • Memory B cells expressing anti-DNP membrane IgG are engineered to express Ig genes encoding a secreted IgG antibody specific for influenza.
  • the anti-influenza IgGi H chain gene i.e., gi-H chain gene
  • the anti-influenza IgGi H chain gene may be engineered to remove coding sequences for the membrane spanning domain (TM), the cytoplasmic amino acids (Cyt), and a polyA addition site to yield a gi-H chain gene encoding a secreted H chain only. See Fig. 3C and Abbas et ak, Ibid.
  • Ig genes are engineered using standard methods in molecular biology (see e.g., Sambrook et ak, In: Molecular Cloning: A Laboratory Manual, 2 nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989 which is incorporated herein by reference) to remove the membrane exons and to retain the promoter and enhancer sequences associated with the functional anti-influenza Ig genes (see e.g ., Abbas et al., Ibid).
  • the Ig H chain and Ig L chain genes encoding the antiviral antibody may be inserted in the non-expressed Ig gene loci by using methods of homologous recombination (see e.g., U.S. Patent No. 5,202,238 issued to Perry et al. on April 13, 1993; U.S. Patent No. 6,570,061 issued to Rajewsky and Zou on May 27, 2003 and U.S. Patent No.
  • nonfunctional immunoglobulin genes are used to target recombination with the anti influenza immunoglobulin genes.
  • the Ig genes encoding the H chain and L chain for a secreted anti-influenza antibody are cloned in plasmid targeting vectors to obtain targeted integration in the corresponding nonfunctional, germline Ig loci on chromosomes 14 and 2 respectively. See Fig. 1 and Fig. 2A.
  • DNA sequences 5’ of the J H segments see Fig.
  • targeting vectors containing target sequences, replacement genes and selectable markers are described (see e.g., U.S. Patent No. 5,202,238 Ibid., U.S. Patent No. 6,570,061 Ibid., and U.S. Patent No. 6,841,383 Ibid ).
  • Targeting vectors encoding a secreted anti-influenza antibody are used to replace the nonfunctional, germline m-H chain gene and the nonfunctional kappa L chain gene in memory B cells expressing membrane anti-DNP IgG.
  • the targeting vector plasmids are linearized by restriction enzyme digestion and transferred by electroporation into the memory B cells followed by selection for the targeting vector plasmids. Methods and reagents for electroporation of primary mammalian cells are described (see e.g., “Electroporation Guide” available from BioRad Inc., Hercules, CA which is incorporated herein by reference).
  • Memory B cells following electroporation, are cultured in tissue culture media containing selection drugs, such as G418 and methotrexate, to select for selectable marker genes, i.e., neomycin resistance gene and dihydrofolate reductase, respectively, present on the H and L chain targeting vectors. Selectable marker genes and their use are described (see e.g ., U.S. Patent No. 6,841,383 Ibid). Electroporated memory B cells with resistance to both G418 and methotrexate are tested for expression of secreted IgG which binds influenza.
  • selection drugs such as G418 and methotrexate
  • HSV-TK Herpes simplex virus- thymidine kinase gene
  • B cells expressing HSV-TK are provided with 20 mM ganciclovir (available as Cytovene IV from Roche Laboratories, Nutley, NJ). Conversion of ganciclovir into a toxic metabolite by the B cells expressing HSV-TK results in their death. Cells not expressing HSV-TK are not harmed by ganciclovir.
  • the recombinant memory B cells may be activated and expanded in vitro to assess their proliferation, activation and production of the secreted anti-influenza antibody.
  • Engineered anti-DNP memory B cells isolated as described above are cultured with DNP- HSA in vitro to activate the cells.
  • memory B cells at about 10 5 tolO 6 cells/mL are cultured in tissue culture flasks in standard media (e.g., RPMI 1640 serum- free media available from Sigma-Aldrich Chem. Co., St. Louis, Mo.) which contain approximately 1 pg/ml of DNP-HSA.
  • standard media e.g., RPMI 1640 serum- free media available from Sigma-Aldrich Chem. Co., St. Louis, Mo.
  • Methods to activate memory B cells are described (see e.g., U.S. Patent No. 7,378,276 Ibid).
  • To assess activation the cells are tested in a proliferation assay after 3-5 days in culture.
  • Purified anti-influenza antibody derived from recombinant cell lines may be used to create standard curves correlating absorbance and antibody concentration in ELISA assays.
  • Supernatants from non- activated, recombinant memory B cells i.e. cultured without DNP-HA serve as negative control samples for the anti -influenza antibody ELISA.
  • the recombinant B lymphocyte cell line can be activated in vivo or ex vivo to produce the secreted broadly neutralizing influenza antibody by injecting the mammalian subject (or an in vitro cell culture) with model antigen, DNP-KLH, to activate production of the secreted antibody from the recombinant B lymphocyte cell line.
  • Timing to stimulate immunological protection from influenza virus infection in the mammalian subject can be chosen based upon the timing of an outbreak of influenza infection in the population at large.
  • B lymphocytes engineered to express a B cell receptor (BCR) recognizing dinitrophenol (DNP) and a secreted antibody recognizing Hepatitis C Virus.
  • BCR B cell receptor
  • DNP dinitrophenol
  • An isolated recombinant B lymphocyte cell line that produces a secreted immunoglobulin against hepatitis C virus (HCV) and produces a membrane
  • immunoglobulin to a model antigen can be utilized for cell therapy in a mammalian subject.
  • the recombinant B lymphocyte cell line can be injected into the mammalian subject as adoptive cell therapy to provide immunological protection from infection by hepatitis C virus.
  • the recombinant B lymphocyte cell line can be activated in vivo or ex vivo to produce secreted anti -HCV antibody by injecting the mammalian subject (or an in vitro cell culture) with model antigen, dinitrophenol-keyhole limpet hemocyanin (DNP- KLH).
  • DNP- KLH dinitrophenol-keyhole limpet hemocyanin
  • Timing to stimulate immunological protection from HCV infection in the mammalian subject can be chosen based upon the timing of exposure of the mammalian subject to HCV or based upon the appearance of symptoms in the subject.
  • Memory B cells expressing membrane IgG are isolated from the peripheral blood of a patient with a chronic hepatitis C virus (HCV) infection.
  • Polyclonal memory B cells are isolated from the patient’s peripheral blood: 1) by isolating peripheral blood mononuclear cells using Ficoll Hypaque density gradients (available from Sigma Aldrich, St. Louis, MO); 2) by negative selection of total B cells using magnetic beads (available from Stem Cell Technology, Vancouver, BC), and 3) by labeling the cells with fluorescent monoclonal antibodies that recognize membrane IgG and CD27, a memory B cell marker, and performing fluorescence- activated cell sorting. See for example, U.S. Patent No. 7,378,276 issued to Ettinger et al. on May 27, 2008 and U.S. Patent No. 7,993,864 issued to Brown et al. on Aug. 9, 2011 which are incorporated herein by reference.
  • Immunoglobulin (Ig) genes encoding a membrane IgG antibody specific for DNP may be obtained from healthy volunteers who are immunized with DNP-KLH (see e.g. , Biosearch Technologies: DNP-KLH Product Info Sheet which is incorporated herein by reference).
  • Memory B cells with membrane IgG recognizing DNP are isolated by cell sorting with a fluorescence-activated cell sorter (e.g., FACSArialll® available from Becton Dickinson, Franklin Lakes, NJ).
  • a fluorescence-activated cell sorter e.g., FACSArialll® available from Becton Dickinson, Franklin Lakes, NJ.
  • Ig genes encoding an anti-DNP antibody are isolated from individual B cells (see e.g., Tiller et al., J. Immunol. Methods 329: 112-124, 2008 which is incorporated herein by reference).
  • the Ig heavy (H) and corresponding Ig light (L) chain gene transcripts are amplified by reverse transcriptase-polymerase chain reaction (RT-PCR) using Superscript ® III reverse transcriptase (available from Invitrogen Corp., Carlsbad, CA) and Taq DNA polymerase (available from Qiagen, Valencia, CA). Reaction conditions and oligonucleotide primers to amplify Ig H chains and Ig L chains are known (see e.g.
  • the DNA fragments encoding the Ig H and L chain variable (V) region genes are isolated and cloned in mammalian expression vectors containing Ig H and L chain constant region genes (e.g, Cyi and Ck).
  • Ig H and L chain constant region genes e.g, Cyi and Ck.
  • DNA sequences of the cloned anti-DNP Ig genes are determined using a DNA sequencer (e.g., using a 3130 Genetic Analyzer available from Applied Biosystems, Carlsbad, CA).
  • the IgGi H chain gene (i.e., gi-H chain gene) is engineered to remove the“tail piece” and polyadenylation site encoding the secreted form of the H chain, thus only a membrane gi-H chain is encoded by the engineered gene (see e.g., Fig. 3B, and Abbas et al., Cellular and Molecular Immunology, 7 th Ed., Elsevier Saunders, Philadelphia, PA, 2012 which is incorporated herein by reference).
  • the cloned gi-H chain gene may be amplified by PCR with primers that amplify the gi-H chain constant region gene but omit the tail piece and polyadenlyation site encoding the secreted form of the gi-H chain (see Fig. 3B).
  • the primer may also add a RNA splice donor site to the 3’ end of the gi-H chain gene and a unique restriction enzyme site (e.g, a site for Not I; enzyme available from New England Biolabs, Ipswich, MA).
  • a separate DNA fragment encoding a RNA splice acceptor site, the membrane anchor exons, and the remainder of the gi-H chain gene are PCR-amplified using PCR primers containing restriction enzyme sites which allow reassembly of the gi-H gene encoding a membrane form of the gi-H chain. See Fig. 3B. Methods to amplify and assemble Ig genes are described (see e.g., ET.S. Patent No. 7,741,077 Ibid).
  • Memory B cells obtained from a patient with a chronic HCV infection are genetically engineered by replacing their functional, expressed Ig genes with Ig genes encoding a membrane IgG(K) which recognizes DNP (see above).
  • the Ig H and L chain genes encoding the anti-DNP antibody may be inserted in the functional, expressed Ig gene loci on chromosomes 14 and 2 by using methods of homologous recombination (see e.g., ET.S. Patent No. 5,202,238 issued to Perry et al. on April 13, 1993; U.S. Patent No. 6,570,061 issued to Rajewsky and Zou on May 27, 2003 and ET.S. Patent No. 6,841,383 issued to Reff et al., on Jan.
  • targeting sequences from the intron between the J H cluster and the m constant region gene are placed 5’ of the anti-DNP g-H chain gene and sequences downstream from the g ⁇ membrane anchor exons are placed 3’ of the g-H chain gene (see Fig. 3 A).
  • Analogous targeting sequences i.e., from the Jk-Ck intron and 3’ of the Ck gene are used for targeting the anti-DNP kappa L chain gene into the functional Ck gene.
  • the targeting vectors for anti-DNP H and L chain include selectable marker genes, e.g., hygromycin resistance and histidinol dehydrogenase, respectively.
  • Media containing hygromycin and histidinol are used to select for engineered mature B cells expressing secreted IgG anti-DNP antibody.
  • Essential transcriptional promoter sequences and enhancer sequences necessary for Ig gene expression are retained in the Ig gene integrants (see Abbas et al., Ibid).
  • those cells producing membrane IgG antibodies specific for DNP are isolated using DNP-KLH attached to magnetic beads (protocols and separation devices are available from Miltenyi Biotec, Auburn, CA).
  • the engineered memory B cells expressing an anti-DNP membrane IgG are engineered to replace their non functional, germline Ig genes with functional Ig genes (for H and L chain).
  • the replacement Ig genes may encode a secreted antibody, an anti-HCV antibody.
  • the Ig genes encoding an anti-viral HCV antibody may be isolated from the chromosomal DNA of a human B cell clone that produces the antiviral antibody.
  • human B cells from an individual immune to HCV are immortalized by infection with Epstein Barr virus (EBV) and supernatants derived from individual B cell clones are tested in an EBV.
  • EBV Epstein Barr virus
  • an EBV-transformed B cell line expressing a human anti-HCV antibody, IgGi(kappa) is grown in culture and used as a source to isolate messenger RNA (mRNA) and genomic DNA using standard methods employing phenol/chloroform (see e.g., Sambrook et al., In: Molecular Cloning: A Laboratory Manual, 2 nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1989).
  • the mRNA encoding the IgGi H-chain and the kappa L-chain are molecularly cloned following amplification using the polymerase chain reaction (PCR) and reverse transcriptase (RT).
  • H and L chain mRNA amplified as complementary DNA
  • a plasmid vector e.g., pCR®2.l-TOPO plasmid available from Invitrogen Corp., Carlsbad, CA
  • V Ig H chain variable
  • the V-region DNA sequences may be determined by automated DNA sequencing (DNA sequencing services are available from Charles River Laboratories International, Inc., Wilmington, MA).
  • genomic DNA isolated from the anti-HCV B cell line is used as a template for PCR amplification of the human H chain gene and kappa L chain gene.
  • PCR primers oligonucleotides
  • V-region genes including their respective promoters and flanking regions upstream (i.e., 5’ of the V genes
  • searching a human genome database with the V- region DNA sequences established from the cloned Ig mRNA.
  • a human genome nucleotide database available from the National Center for Biotechnology
  • BLAST Human RefSeq Genome database and BLAST software are available online (see e.g ., http://blast.ncbi.nlm.nih.gov/Blast.cgi). Primers to amplify the Ig constant regions, enhancer sequences, the H-chain membrane anchors, poly A addition sites and downstream flanking regions (i.e., 3’ of the Ig gene) are described (see e.g, U.S. Patent No. 7,741,077 Ibid.).
  • the PCR-amplified, genomic fragments can be cloned in a plasmid vector such as pCR®2.l-TOPO available from Invitrogen Corp., Carlsbad, CA).
  • Memory B cells expressing an anti-DNP membrane IgG antibody are engineered to express Ig genes encoding a secreted IgG antibody specific for HCV.
  • the anti-HCV IgG H chain gene i.e ., g-H chain gene
  • Ig genes are engineered using standard methods in molecular biology (see e.g., Sambrook et ak, In: Molecular Cloning: A Laboratory Manual, 2 nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989 which is incorporated herein by reference) to remove the membrane exons and to retain the promoter and enhancer sequences associated with the functional anti-HCV Ig genes (see e.g, Abbas et ak, Ibid).
  • the Ig H and L chain genes encoding the antiviral antibody may be inserted in the non- expressed Ig gene loci by using methods of homologous recombination (see e.g., U.S. Patent No. 5,202,238 Ibid., U.S. Patent No. 6,570,061 Ibid and U.S. Patent No. 6,841,383 Ibid).
  • the Ig genes encoding the H chain and L chain for a secreted anti-HCV antibody are cloned in plasmid targeting vectors to obtain targeted integration in the corresponding germline Ig loci on chromosomes 14 and 2 respectively. See Fig. 1.
  • sequences 5’ of the J H segments upstream from the germline m-H chain gene see Fig.
  • Targeted Chromosome 14 Germline Configuration are cloned upstream (5’) of the anti-HCV g-H chain gene in a targeting plasmid, and sequences downstream (3’) of the m-H chain membrane anchor exons are cloned downstream (3’) of the g-H chain gene to promote recombination at the germline H-chain locus on chromosome 14.
  • Methods for construction of targeting vectors containing target sequences, replacement genes and selectable markers are described (see e.g., U.S. Patent No. 5,202,238 Ibid., U.S. Patent No. 6,570,061 Ibid., and U.S. Patent No. 6,841,383 Ibid).
  • Targeting vectors encoding a secreted anti-HCV antibody are used to replace the nonfunctional, germline m-H chain gene and the nonfunctional kappa L chain gene in memory B cells expressing membrane anti-DNP.
  • the targeting vector plasmids are linearized by restriction enzyme digestion and transferred by electroporation into the memory B cells followed by selection for the targeting vector plasmids. Methods and reagents for electroporation of primary mammalian cells are described (see e.g., “Electroporation Guide” available from BioRad Inc., Hercules, CA which is incorporated herein by reference).
  • Memory B cells following electroporation, are cultured in tissue culture media containing drugs such as G418 and methotrexate to select for selectable marker genes (i.e., neomycin resistance gene and dihydrofolate reductase, respectively) present on the H and L chain targeting vectors. Selectable marker genes and their use are described (see e.g, U.S. Patent No. 6,841,383 Ibid). Electroporated memory B cells with resistance to both G418 and methotrexate are tested for expression of secreted IgG which binds HCV.
  • selectable marker genes i.e., neomycin resistance gene and dihydrofolate reductase, respectively
  • the engineered memory B cells expressing two different antibodies may be activated in vitro and assayed for proliferation and production of the secreted anti-HCV antibody.
  • Engineered anti-DNP memory B cells are cultured in vitro with dinitrophenol- human serum albumin (DNP-HSA is available from Biosearch Technologies, Novato, CA) to activate the cells.
  • DNP-HSA dinitrophenol- human serum albumin
  • memory B cells at about 10 5 tolO 6 cells/mL are cultured at 37° C in tissue culture flasks in standard media (e.g., RPMI 1640 serum-free media available from Sigma-Aldrich Chem. Co., St. Louis, Mo.) which contain approximately 1 pg/ml of DNP-HSA.
  • memory B cell cultures may include 1 pg/ml of anti- CD40 antibody and 100 ng/ml of interleukin-21 (both are available from R&D Systems, Minneapolis, MN) to activate the cells and promote antibody production. Methods to activate memory B cells are described (see e.g., U.S. Patent No. 7,378,276 Ibid). To assess activation the cells are tested in a proliferation assay after 3-5 days in culture.
  • ELISA enzyme-linked immunosorbent assay
  • a purified anti-HCV antibody produced by a recombinant cell line may be used to create standard curves for determining antibody concentration in the ELISA assay.
  • Supernatants from engineered memory B cells that are not activated i.e. cultured without DNP-HSA serve as negative control samples for the anti-HCV antibody ELISA.
  • HSV-TK Herpes simplex virus-thymidine kinase gene
  • ganciclovir Conversion of ganciclovir into a toxic metabolite by the B cells expressing HSV-TK results in their death.
  • Cells not expressing HSV-TK are not harmed by ganciclovir.
  • Engineered memory B cells expressing an anti-DNP BCR and an anti-viral (anti- HCV) secreted antibody may be expanded and used for adoptive cell therapy of the patient with chronic HCV infection.
  • the B cells may be activated in vitro (as described above) or in vivo by administration of DNP-HSA to the patient. Immunization with approximately 100 mg DNP-KLH administered subcutaneously may be done to activate the engineered memory B cells (see e.g ., Rentenaar et al., Ibid.). Multiple activations may be stimulated to respond to HCV infections.
  • Mature B lymphocytes engineered to express a membrane antibody specific for prostate specific antigen and a second, secreted antibody specific for prostate cancer lipid antigen.
  • An isolated recombinant B lymphocyte cell line that produces a secreted immunoglobulin against prostate cancer lipid antigen (PCLA) and produces a membrane immunoglobulin to prostate specific antigen (PSA) can be utilized for cell therapy to treat prostate cancer in a mammalian subject.
  • the recombinant B lymphocyte cell line can be injected into the mammalian subject as adoptive cell therapy to provide immunological reactivity to PSA on prostate cancer cells and to process and present PSA to T
  • the recombinant B lymphocyte cell line can be activated by endogenous PSA arising in the subject to produce secreted anti -PCLA antibody.
  • the recombinant B lymphocyte cell line can also be activated in vivo or ex vivo by injecting the mammalian subject (or an in vitro cell culture) with exogenous prostate specific antigen (PSA) to produce secreted anti-PCLA antibody. Determination of timing to stimulate
  • immunological reactivity to prostate cancer cells in the mammalian subject can be chosen based upon the detection of prostate cancer cells in the mammalian subject.
  • BCR B cell receptors
  • Mature B cells may be obtained from peripheral blood leukocytes of the patient. For example approximately 10 9 leukocytes may be harvested using a leukapheresis procedure (see e.g., Bensinger et al., Blood 81: 3158-3163, 1993 which is incorporated herein by reference) and approximately 5% (i.e., 5xl0 7 cells) are B cells.
  • Mature B cells are isolated from the patient’s leukocytes by using antibodies specific for B cell markers CD 19, IgD, CD38, and CD21 (available from Becton Dickinson/Pharmingen, San Diego, CA).
  • Mature B cells are genetically engineered to express a membrane IgG antibody specific for prostate specific antigen (PSA).
  • PSA is a protein antigen associated with prostate cancer that may be produced using recombinant DNA methods and purified for use as an antigen (see e.g., U.S. Patent No. 8,013,128 issued to Gudas et al. on Sept. 6, 2011 which is incorporated herein by reference).
  • Ig human immunoglobulin
  • transgenic mice with human Ig genes are immunized with PSA and their B cells are fused with a myeloma cell fusion partner, e.g. SP2/0 cells (available from American Type Culture Collection, Manassas, VA) to create hybridoma cell clones expressing human antibodies (see e.g, U.S. Patent No. 8,013,128 Ibid).
  • a myeloma cell fusion partner e.g. SP2/0 cells (available from American Type Culture Collection, Manassas, VA) to create hybridoma cell clones expressing human antibodies (see e.g, U.S. Patent No. 8,013,128 Ibid).
  • Supernatants from the hybrid clones are screened using an immunoassay to detect human IgG antibodies which bind PSA protein.
  • Hybridoma clones producing antibodies that recognize PSA are expanded and antibodies from each clone are tested using a BiacoreTM A100 instrument (available from GE Healthcare, Piscataway, NJ) to measure antibody affinity and specificity for PSA (see e.g., GE Healthcare, Application Note 84,“Early kinetic screening of hybridomas.. which is incorporated herein by reference).
  • Hybridomas expressing high affinity antibodies for PSA are selected for cloning of their human Ig genes. Methods to clone Ig heavy (H) chain and light (L) chain genes may be used. See e.g., U.S. Patent No. 7,741,077 issued to Granch et al.
  • a hybridoma cell line expressing a human anti-PSA antibody, IgGi(kappa) is grown in culture and used as a source to isolate messenger RNA (mRNA) and genomic DNA using standard methods employing phenol/chloroform (see e.g., Sambrook et al., In: Molecular Cloning: A Laboratory Manual, 2 nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1989).
  • the mRNA encoding the IgGi H-chain and the kappa L-chain are molecularly cloned following amplification using the polymerase chain reaction (PCR) and reverse transcriptase (RT). Methods and Ig gene primers to amplify the H chain and L chain mRNA are described in U.S. Patent No. 7,741,077 Ibid.
  • the H and L chain mRNA (amplified as complementary DNA) are cloned in a plasmid vector (e.g ., pCR®2.l-TOPO plasmid available from Invitrogen Corp., Carlsbad, CA) and the DNA sequence of the Ig H chain variable (V) region (including the Vh, D and J segments) and the kappa L chain V-region (including the Vk and Jk segments) are determined.
  • V-region DNA sequences may be determined by automated DNA sequencing (DNA sequencing services are available from Charles River Laboratories International, Inc., Wilmington, MA).
  • PCR primers oligonucleotides
  • V-region genes including their respective promoters and flanking regions upstream (i.e., 5’ of the V genes
  • searching a human genome database with the V-region DNA sequences established from the cloned Ig mRNA.
  • BLAST human genome nucleotide database available from the National Center for Biotechnology Information can be searched with a computer program, BLAST, for sequences matching the H- and L-chain V-regions.
  • downstream flanking regions i.e., 3’ of the Ig gene
  • the PCR-amplified, genomic fragments can be cloned in a plasmid vector such as pCR®2. l-TOPO available from Invitrogen Corp., Carlsbad, CA).
  • the IgGi H chain gene i.e., gi-H chain gene
  • the cloned gi-H chain gene may be amplified by PCR with primers that amplify the gi-H chain constant region gene but omit the tail piece and polyadenlyation site encoding the secreted form of the gi-H chain.
  • the primer may also add a RNA splice donor site to the 3’ end of the gi-H chain gene and a unique restriction enzyme site (e.g, a site for Not I; enzyme available from New England Biolabs, Ipswich, MA).
  • the Ig genes encoding the H chain and L chain for an anti -PS A membrane antibody are cloned in plasmid targeting vectors to obtain targeted integration in the corresponding nonfunctional germline Ig loci on chromosomes 14 and 2 respectively. See Fig. 1.
  • sequences 5’ of the J H genes are cloned upstream (5’) of the anti -PS A gi-H chain gene in a targeting plasmid
  • sequences downstream (3’) of the m-H chain membrane anchor exons (TM and Cyt) are cloned downstream (3’) of the gi-H chain gene to promote recombination at the germline H-chain locus on chromosome 14.
  • Targeting vectors constructed to replace the nonfunctional germline m-H chain gene and the nonfunctional kappa L chain gene in mature B cells are transferred into mature B cells in vitro.
  • the targeting vector plasmids are linearized by restriction enzyme injection and transferred by electroporation into the mature B cells followed by selection for the targeting vector plasmids.
  • Mature B cells following electroporation are cultured in tissue culture media containing drugs such as G418 and methotrexate to select for selectable marker genes (i.e., neomycin resistance gene and dihydrofolate reductase, respectively) present on the H and L chain targeting vectors.
  • selectable marker genes i.e., neomycin resistance gene and dihydrofolate reductase, respectively.
  • Electroporated mature B cells with resistance to both G418 and methotrexate are tested for expression of membrane IgG which binds PSA.
  • engineered mature B cells expressing membrane IgG specific for PSA are isolated using magnetic beads with PSA attached, and the cells are propagated in vitro prior to transfection with Ig genes for a second antibody specific for a different prostate tumor associated antigen.
  • Mature B cells expressing an anti-PSA membrane IgG antibody are engineered to express Ig genes encoding a secreted IgG antibody specific for prostate cancer lipid antigen (PCLA).
  • PCLA prostate cancer lipid antigen
  • Methods to extract PCLA and to obtain a monoclonal antibody specific for PCLA are known (see e.g., Zhang et al., Proc. Natl. Acad. Sci. USA 107: 732-737, 2010 which is incorporated herein by reference).
  • a human IgG antibody specific for PCLA and the corresponding Ig genes may be obtained as described above (see e.g., U.S. Patent No. 7,741,077 Ibid and Early et al., Ibid).
  • the anti-PCLA IgG H chain gene (i.e., g-H chain gene) may be engineered to remove coding sequences for the membrane spanning domain and the cytoplasmic amino acids to yield a g-H chain gene encoding a secreted H chain only. See Fig. 3 and Abbas et al., Ibid.
  • the anti-PCLA Ig genes are integrated into the functionally rearranged Ig gene loci of the mature B cell which include the m-H chain gene on chromosome 14 and the kappa L chain gene on chromosome 2 (e.g, see Fig. 2; only the H chain gene is shown).
  • Targeted integration of the anti-PCLA g-H chain gene and L chain gene into the corresponding functional H and L chain gene loci is done using methods of homologous recombination as described above (see U.S. Patent No. 6,570,061 Ibid., and U.S. Patent No. 6,841,383 Ibid).
  • targeting sequences from the intron between the J H cluster and the m constant region gene (CHP) are placed 5’ of the anti-PCLA g-H chain gene and sequences downstream from the m membrane anchor exons are placed 3’ of the g-H chain gene (see Fig. 2).
  • Analogous targeting sequences are used for targeting the anti-PCLA kappa light chain gene to the functional Ck gene.
  • the targeting vectors for anti-PCLA H and L chain include different selectable marker genes, hygromycin resistance and histidinol dehydrogenase, respectively.
  • Media containing hygromycin and histidinol is used to select for engineered mature B cells expressing secreted IgG anti-PCLA antibody.
  • Essential transcriptional promoter sequences and enhancer sequences necessary for Ig gene expression are retained in the Ig gene integrants (see Abbas et al., Ibid).
  • the engineered mature B cells are cultured in vitro and stimulated with PSA to activate the cells and to stimulate secretion of anti-PCLA IgG antibodies.
  • HSV-TK Herpes simplex virus-thymidine kinase gene
  • ganciclovir Conversion of ganciclovir into a toxic metabolite by the B cells expressing HSV-TK results in their death. Cells not expressing HSV-TK are not harmed by ganciclovir.
  • the isolated recombinant B lymphocytes are administered to prostate cancer patients to provide antibodies to PCLA and to process and present PSA to T cells.
  • Autologous B cells engineered to express anti-PSA membrane IgG and anti-PCLA secreted IgG are cultured in vitro with approximately 1 pg/mL PSA for approximately 3 to 5 days and then washed in serum-free media prior to injection. Approximately 5-10 X 10 8 B cells are injected intravenously and the concentration of anti-PCLA antibodies and the number of engineered B cells in the peripheral blood of the patient are monitored with immunoassays and flow cytometry respectively.
  • Memory B lymphocytes from patients vaccinated with influenza vaccine are provided with membrane antibodies specific for DNP and activated by
  • An isolated recombinant B lymphocyte cell line that produces a secreted broadly neutralizing immunoglobulin to influenza virus and produces a membrane
  • immunoglobulin to a model antigen can be utilized for cell therapy in a mammalian subject.
  • the recombinant B lymphocyte cell line can be injected into the mammalian subject as cell therapy to provide immunological protection from infection by influenza virus.
  • the recombinant B lymphocyte cell line can be activated in vivo or ex vivo to produce the broadly neutralizing influenza antibody by injecting the mammalian subject (or an in vitro cell culture) with model antigen, dinitrophenol-keyhole limpet hemocyanin (DNP-KLH).
  • DNP-KLH dinitrophenol-keyhole limpet hemocyanin
  • the timing to stimulate immunological protection from influenza virus infection in the mammalian subject can be chosen based upon the timing of an outbreak of influenza infection in the population at large.
  • An individual is immunized with an influenza vaccine to obtain memory B cells with B cell receptors (BCR) specific for influenza virus.
  • BCR B cell receptors
  • Memory B cells develop in response to immunization with a subunit vaccine for influenza virus which may elicit broadly neutralizing antibodies (see e.g ., Ekiert et al., Science 324: 246-251, 2009 which is incorporated herein by reference).
  • a primary immunization with 1 mg of influenza virus vaccine for example, a conserved epitope from the viral hemagglutinin (HA) protein is injected subcutaneously in the right arm.
  • HA hemagglutinin
  • Influenza-specific memory B cells are isolated by cell sorting with a fluorescence activated cell sorter (e.g, FACSArialll® available from Becton Dickinson, Franklin Lakes, NJ).
  • a fluorescence activated cell sorter e.g, FACSArialll® available from Becton Dickinson, Franklin Lakes, NJ.
  • Memory B cells expressing membrane IgG specific for an influenza HA epitope are cultured in vitro and expanded prior to transfection with a membrane immunoglobulin specific for
  • DNP dinitrophenol
  • tissue culture flasks in standard media (e.g., RPMI 1640 serum-free media available from Sigma-Aldrich Chem. Co., St. Louis, Mo.) which contain
  • memory B cell cultures may include 1 pg/ml of anti-CD40 antibody and 100 ng/ml of interleukin-21 (both are available from R&D Systems, Minneapolis, MN) to activate the cells (see e.g., ET.S. Patent No. 7,378,276 Ibid).
  • a membrane immunoglobulin specific for DNP is produced using recombinant DNA methods and inserted in the membrane of memory B cells producing anti-influenza antibodies.
  • Immunoglobulin (Ig) genes encoding a membrane IgG antibody specific for DNP may be obtained from healthy volunteers who are immunized with DNP-KLH (see e.g, Biosearch Technologies DNP- KLH Product Info Sheet which is incorporated herein by reference).
  • Memory B cells with membrane IgG recognizing DNP are isolated by cell sorting with a fluorescence-activated cell sorter (e.g, FACSArialll® available from Becton Dickinson, Franklin Lakes, NJ).
  • a fluorescence-activated cell sorter e.g, FACSArialll® available from Becton Dickinson, Franklin Lakes, NJ.
  • Immunoglobulin genes encoding an anti-DNP antibody are isolated from individual B cells (see e.g., Tiller et al., J. Immunol. Methods 329: 112-124, 2008 which is incorporated herein by reference). For each individual anti-DNP B cell the Ig heavy (H) and corresponding Ig light (L) chain gene transcripts are amplified by reverse
  • RT-PCR transcriptase-polymerase chain reaction
  • Superscript® III reverse transcriptase available from Invitrogen Corp., Carlsbad, CA
  • Taq DNA polymerase available from Qiagen, Valencia, CA
  • Reaction conditions and oligonucleotide primers to amplify Ig H chains and Ig L chains are known (see e.g. Tiller et al., Ibid.).
  • the DNA fragments encoding the Ig H and Ig L chain variable (V) region genes are isolated and cloned in mammalian expression vectors containing Ig H and Ig L chain constant region genes (e.g, Cyl and Ck).
  • DNA sequences of the cloned anti-DNP Ig genes are determined using a DNA sequencer (e.g., using a 3130 Genetic Analyzer available from Applied Biosystems, Carlsbad, CA).
  • the IgGi H chain gene i.e., yi-H chain gene
  • the IgGi H chain gene is engineered to remove the“tail piece” and polyadenylation site encoding the secreted form of the H chain, thus only a membrane yi-H chain is encoded by the engineered gene (see e.g., Fig. 3B, and Abbas et al., Cellular andMolecular
  • the cloned yi-H chain gene may be amplified by PCR with primers that amplify the yi-H chain constant region gene but omit the tail piece and polyadenlyation site encoding the secreted form of the yi-H chain.
  • a separate DNA fragment encoding the yi membrane anchor exons, and the remainder of the yi-H chain gene are PCR-amplified using PCR primers containing restriction enzyme sites which allow reassembly of the yi-H gene encoding a membrane form of the yi-H chain. See Fig. 3B. Methods to amplify and assemble Ig genes are described (see e.g., ET.S. Patent No. 7,741,077 Ibid).
  • the genetically engineered immunoglobulin genes encoding the anti-DNP membrane antibody are expressed in a mammalian cell line and the membrane IgG is purified from the cell line.
  • a kappa (K) L chain gene and the modified y-l H chain gene are inserted in a lentiviral expression vector using standard recombinant DNA methods (see e.g., ET.S. Patent Publication No. 2007/0116690 by Yang et al. published on May 24, 2007 which is incorporated herein by reference).
  • the viral vector is used to transfect Chinese Hamster Ovary (CHO) cells (available from American Type Culture Collection, Manassus, VA) which are engineered to express membrane immunoglobulin.
  • membrane immunoglobulins may be used. See e.g. , Price et al., J. Immunol. Methods 343: 28-41, 2009 which is incorporated herein by reference.
  • a phycoerythrin- conjugated anti-human IgG antibody was used to label CHO cells and sort them using FACS (see e.g., Price et al., Ibid).
  • a CHO cell line producing anti-DNP membrane IgG is isolated and expanded and membrane IgG is purified from CHO cell lysates using an immunoaffmity column.
  • An affinity column constructed from protein A-Sepharose available from Sigma-Aldrich Co., St.
  • membrane IgG is used to purify membrane IgG from lysates of the engineered CHO cells.
  • cells may be lysed in a buffer containing: 0.15 M NaCl, 0.01 M TrisHCl, pH 8.2, 1 mM EDTA, 2mM
  • phenylmethylsulfonyl fluoride 0.5% Nonidet P-40 and 1 mg/mL HSA (see e.g., Schneider et al., J. Biol. Chem. 257: 10766-10769, 1982 which is incorporated herein by reference).
  • the purified anti-DNP membrane IgG is used to construct liposomes which are fused to memory B cells specific for influenza antigen (see above).
  • Liposomes containing anti-DNP membrane IgG are constructed from
  • Liposomes may be fused with memory B cells specific for influenza virus to obtain memory B cells with anti-DNP membrane immunoglobulin incorporated into the B cell membrane.
  • Liposomes may be prepared from cholesterol and L-a-phosphatidylcholine. See e.g, U.S. Patent Publication No. 2005/0208120, which is incorporated herein by reference. Cholesterol and L- a- phosphatidyl choline are combined at a molar ratio of 2:7 in chloroform and the chloroform is evaporated away using an argon stream.
  • the liposomes are resuspended in a 140 mM NaCl, 10 mM Tris HCI, 0.5% deoxycholate at pH 8 and sonicated for three minutes.
  • Purified anti-DNP membrane antibodies (see above) are inserted into the liposomes by combining the membrane IgG with liposomes at a 1 : 10 molar ratio and dialyzing for 72 hours at 4° C versus phosphate buffered saline.
  • the liposomes are characterized to assess liposome size and the amount of anti-DNP membrane IgG protein incorporated into the liposomes. Liposome size is determined using dynamic light scattering and flow cytometry (see e.g, U.S. Patent Application No.
  • liposomes containing anti-DNP antibodies may have a mean diameter of approximately 50 nanometers.
  • Anti-DNP IgG protein on the liposomes is measured using an enzyme-linked immunosorbent assay (ELISA). Methods to analyze liposomes by flow cytometry and to measure IgG and other proteins by ELISA are known (see e.g. , U.S. Patent Application No. 2005/0208120, Ibid.).
  • Liposomes containing anti-DNP membrane IgG are fused with memory B cells specific for influenza virus (see above) to obtain memory B cells with anti-DNP B cell receptor.
  • Purified liposomes with anti-DNP BCR on their surface are electrofused with the memory B cells (see e.g., Zimmermann et ak, IEEE Transactions On Plasma Science 28: 72-82, 2000 which is incorporated herein by reference).
  • a 1 : 1 ratio of liposomes to memory B cells are suspended in a hypo-osmolar buffer containing 0.1 mM Ca-acetate, 0.5 mM Mg-acetate and 1 mg/ml bovine serum albumin.
  • the osmolarity is adjusted to approximately 75 mOsm and approximately 200 pL of the cell suspension containing approximately 2 X 10 4 to 2 X 10 5 cells is placed in an electrofusion chamber (electrofusion generators and chambers are available from BTX Instrument Division, Harvard Apparatus, Inc. Holliston, MA).
  • the cells are aligned by applying an alternating field of 5 V amplitude and 2MHz frequency for approximately 30 seconds.
  • fusion is initiated by applying a rectangular fusion pulse of 20V to 40V amplitude and of 15 psec duration.
  • the alternating field is applied again for 30 seconds to maintain cells and liposomes in position while fusion occurs.
  • the cells are transferred to culture flasks and grown for 2 to 5 weeks.
  • the fused memory B cells are characterized to assess their anti-DNP BCRs and their production of anti-influenza antibodies.
  • the fused memory B cells are tested for membrane anti-DNP antibodies using fluorescent DNP-HSA and FACS analysis.
  • the fused memory B cells may be activated in vitro to produce anti-influenza antibodies when stimulated with DNP-HSA, and the production of secreted anti-influenza virus antibodies may be measured using an ELISA based upon influenza viral hemagglutinin protein or influenza virions.
  • Methods to measure anti-influenza antibodies and memory B cell activation are known (see e.g., U.S. Patent No. 7,378,276 Ibid and Example 1).
  • the human patient at risk of influenza viral infection is given recombinant fused memory B cells as a therapeutic and prophylactic cell therapy which can be activated in vivo.
  • the recombinant memory B cells are activated in vivo by administration of DNP- HSA to the patient when an anti -influenza antibody response is needed.
  • DNP- HSA a prophylactic when the patient is healthy prior to“flu season.”
  • the fused memory B cells may be activated when needed by intracutaneous injection of 100 pg of DNP-HSA to the patient.
  • the fused memory B cells may be activated after the patient is exposed to influenza virus or at the first signs of infection.
  • the production of anti -influenza antibodies may be monitored by sampling the patient’s peripheral blood and performing ELISA with influenza virions as the antigen.
  • the presence of broadly neutralizing antibodies for multiple strains of influenza virus can be determined by ELISA based on conserved epitopes from influenza virus (see e.g., Ekiert et ak, Ibid.)
  • An isolated recombinant B lymphocyte cell line that produces two different secreted immunoglobulins to methicillin-resistant Staphylococcus aureus (MRSA) and produces a membrane immunoglobulin to a third S. aureus antigen can be utilized for cell therapy in a mammalian subject.
  • the recombinant B lymphocyte cell line can be injected into the mammalian subject as cell therapy to provide immunological protection from infection by MRSA.
  • the recombinant B lymphocyte cell line can be activated in vivo or ex vivo to produce antibody to MRSA by injecting the mammalian subject (or an in vitro cell culture) with S. aureus antigen.
  • the timing to stimulate immunological protection from MRSA infection in the mammalian subject can be chosen based upon the exposure of the subject to MRSA or the appearance of symptoms of MRSA infection.
  • MRSA methicillin-resistant Staphylococcus aureus
  • MAb Aureus monoclonal antibodies
  • Memory B cells expressing membrane IgG also known as surface IgG or B cell receptor (BCR)
  • BCR B cell receptor
  • Polyclonal memory B cells with unknown antigen specificities are isolated from the patient’s peripheral blood: 1) by isolating peripheral blood mononuclear cells using Ficoll Hypaque density gradients (available from Sigma Aldrich, St.
  • immunoglobulin (Ig) genes encoding two different anti -A aureus antibodies.
  • Ig genes encoding a first anti -A aureus IgG antibody are isolated from a hybridoma cell line which produces the antibody.
  • Methods to construct a hybridoma cell line producing an IgG antibody specific for poly-N-acetylglucosamine (PNAG) which is protective against A aureus are described (see e.g. , Kelly-Quintos et al., Infection and Immunity 74: 2742-2750, 2006 which is incorporated herein by reference).
  • transgenic mice with human Ig genes are immunized with PNAG and their B cells are fused with a myeloma cell fusion partner, e.g. SP2/0 cells (available from American Type Culture Collection, Manassas, VA) to create hybridoma cell clones expressing human antibodies (see e.g, U.S Patent No. 8,013,128 Ibid.)
  • Hybridomas expressing high affinity antibodies for PNAG are selected for cloning of their Ig genes.
  • Methods to clone Ig heavy (H) chain and light (L) chain genes are known (see e.g., U.S.
  • Patent No. 7,741,077 issued to Granch et al. on June 22, 2010 and Early et al., Proc. Natl. Acad. Sci. USA 76: 857-861,1979 which are incorporated herein by reference).
  • a hybridoma cell line expressing an anti- PNAG antibody, IgGi(kappa) is grown in culture and used as a source to isolate messenger RNA (mRNA) and genomic DNA using standard methods employing phenol/chloroform (see e.g., Sambrook et al., In: Molecular Cloning: A Laboratory Manual, 2 nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1989).
  • the mRNA encoding the IgGi H-chain and the kappa L-chain are molecularly cloned following amplification using the polymerase chain reaction (PCR) and reverse transcriptase (RT). Methods and Ig gene primers to amplify the H chain and L chain mRNA are described in U.S. Patent No. 7,741,077 Ibid.
  • the H and L chain mRNA (amplified as complementary DNA) are cloned in a plasmid vector (e.g., pCR®2.
  • V-TOPO plasmid available from Invitrogen Corp., Carlsbad, CA
  • DNA sequence of the Ig H chain variable (V) region including the Vh, D and J segments
  • kappa L chain V-region including the Vk and Jk segments
  • the V-region DNA sequences may be determined by automated DNA sequencing (DNA sequencing services are available from Charles River Laboratories International, Inc., Wilmington, MA).
  • genomic DNA isolated from the anti-PNAG hybridoma, as isolated above is used as a template for PCR amplification of the H chain gene and kappa L chain gene.
  • PCR primers oligonucleotides
  • V-region genes including their respective promoters and flanking regions upstream (i.e., 5’ of the V genes
  • searching a human genome database with the V- region DNA sequences established from the cloned Ig mRNA.
  • a human genome nucleotide database available from the National Center for Biotechnology
  • BLAST Human RefSeq Genome database and BLAST software are available online (see e.g ., the world wide web at blast.ncbi.nlm.nih/gov/blast.cgi). Primers to amplify the Ig constant regions, enhancer sequences, the H-chain membrane anchors, poly A addition sites and downstream flanking regions (i.e., 3’ of the Ig gene) are described (see e.g., U.S. Patent No. 7,741,077 Ibid ).
  • the PCR-amplified, genomic fragments can be cloned in a plasmid vector such as pCR®2. l-TOPO available from Invitrogen Corp., Carlsbad, CA).
  • the IgGi H chain gene i.e., gi-H chain gene
  • the IgGi H chain gene may be engineered to remove the“tail piece” and polyadenylation site encoding the secreted form of the H chain, thus only a membrane gi-H chain is encoded by the engineered gene (see e.g., Fig. 3B, and Abbas et ak, Cellular and Molecular Immunology, 7 th Ed., Elsevier Saunders, Philadelphia, PA, 2011 which is incorporated herein by reference).
  • the cloned gi-H chain gene may be amplified by PCR with primers that amplify the gi-H chain constant region gene but omit the tail piece and polyadenlyation site encoding the secreted form of the gi-H chain.
  • Separate DNA fragments encoding the membrane anchor exons and the remainder of the gi-H chain gene are PCR-amplified using PCR primers containing restriction enzyme sites which allow reassembly of the gi-H gene encoding a membrane form of the gi-H chain. See Fig. 3B. Methods to amplify and assemble Ig H and L chain genes are described (see e.g., U.S. Patent No. 7,741,077 Ibid).
  • the Ig genes encoding the heavy (H) chain and light (L) chain of the anti-PNAG antibody are cloned in targeting plasmid vectors to allow targeted integration at and replacement of the corresponding functionally rearranged Ig H and Ig L chain genes on chromosomes 14 and 2 respectively ( e.g ., See Fig. 1).
  • Methods to target genes to Ig loci using homologous recombination are known (see e.g., U.S. Patent No. 5,202,238 issued to Perry et al. on April 13, 1993; U.S. Patent No. 6,570,061 issued to Rajewsky and Zou on May 27, 2003 and U.S. Patent No. 6,841,383 issued to Reff et al.
  • targeting sequences from the intron between the J H cluster and the m constant region gene (C H P; see Fig. 2A) are placed 5’ of the anti-PNAG g-H chain gene and sequences downstream from the g ⁇ membrane anchor exons are placed 3’ of the g-H chain gene (see Fig. 3 A).
  • Analogous targeting sequences i.e., from the J K -C K intron and 3’ of the C K gene
  • the targeting vectors for anti-PNAG H and L chain include selectable marker genes, e.g., hygromycin resistance and ZeocinTM bleomycin resistance, respectively.
  • hygromycin B and ZeocinTM bleomycin are used to select for engineered memory B cells expressing membrane IgG anti-PNAG antibody (Protocols, selection agents and selectable markers are available from Invitrogen, Carlsbad, CA). Essential transcriptional promoter sequences and enhancer sequences necessary for Ig gene expression are retained in the Ig replacement genes (see Abbas et al., Ibid ).
  • recombinant memory B cells expressing membrane IgG specific for S. aureus PNAG are isolated using magnetic beads with PNAG attached (magnetic beads and protocols are available from Miltenyi Biotech Inc., Auburn, CA).
  • Memory B cells expressing the anti-PNAG membrane antibody are cultured in vitro prior to transfection with Ig genes encoding a second antibody specific for a different S. aureus antigen.
  • Memory B cells are produced using recombinant DNA methods to express a membrane antibody specific for PNAG and are further genetically engineered to express a second anti -A aureus MAb.
  • IsaA immunodominant staphylococcal antigen A
  • a hybridoma cell line is constructed using purified recombinant IsaA protein to immunize mice and select hybridoma clones (see e.g., Lorenz et al., Antimicrob. Agents Chemoth. 55: 165-173, 2011 which is incorporated herein by reference).
  • messenger RNA is extracted from a selected hybridoma cell line and used as a template for complementary DNA synthesis with reverse transcriptase (RT) and amplification using polymerase chain reaction (PCR) (i.e., RT- PCR).
  • RT reverse transcriptase
  • PCR polymerase chain reaction
  • a plasmid expression vector encoding a complete gamma (g)-1 H chain and a lambda (l) L chain may be constructed using restriction enzymes and standard molecular biology methods (see e.g., Sambrook et al., Ibid).
  • the yl-H chain gene and the l-L chain gene may be transferred to a lentiviral vector (see e.g, U.S. Patent No. 7,939,059 issued to Yang et al. on May 10, 2011 which is incorporated herein by reference).
  • Infection of memory B cells with the recombinant lentivirus results in integration of the vector sequences at random sites (i.e., not targeted) in the genomic DNA of the memory B cells and production of the secreted IgGl (l) anti-IsaA antibody.
  • Protocols and lentiviral expression vectors are available from Invitrogen Corp., Carlsbad, CA; see e.g., User Manual:“ViraPowerTM HiPerfomTM Lentiviral Expression System” which is incorporated herein by reference.
  • a flask of memory B cells is infected with titered recombinant lentivirus stock so as to yield a multiplicity of infection of approximately 1.0 transducing units per cell.
  • the cells and lentivirus are incubated overnight at 37° C in 5% C0 2; then, the lentivirus containing media is replaced by fresh media and incubated overnight.
  • the cells are placed in selective media (e.g, media containing blasticidin is available from Invitrogen Corp., Carlsbad, CA) to select for stably transduced cells containing the lentiviral vector.
  • selective media e.g, media containing blasticidin is available from Invitrogen Corp., Carlsbad, CA
  • Clones of memory B cells resistant to blasticidin are also placed under selection for hygromycin B and ZeocinTM to select clones expressing both anti-MRSA antibodies.
  • memory B cells with surface IgG specific for PNAG are purified using magnetic beads (available from Miltenyi Biotec Inc., Auburn, CA) and cultured in vitro with PNAG. Methods to obtain PNAG and culture conditions for human memory B cells are described (see e.g., Kelly-Quintos et al., Ibid and U.S. Patent No. 7,378,276, Ibid). Supernatants from the cultures are tested for anti-IsaA IgG antibody with an ELISA (see e.g, Lorenz et al., Ibid) and memory B cells producing anti-IsaA antibody are selected and expanded for adoptive immunotherapy.
  • the human patient at risk of MRS A infection is given recombinant memory B cells as a therapeutic and prophylactic cell therapy which can be activated in vivo.
  • the recombinant memory B cells are activated in vivo by administration of S. aureus antigen to the patient when an anti-MRSA antibody response is needed.
  • S. aureus antigen for example, approximately 10 8 -10 9 recombinant B cells may be injected as a prophylactic when the patient is healthy or has been recently infected with MRSA.
  • the recombinant memory B cells may be activated when needed by intracutaneous injection of 100 pg of S. aureus antigen to the patient.
  • the memory B cells may be activated after the patient is exposed to MRSA or at the first signs of infection.
  • the production of anti- MRSA antibodies may be monitored by sampling the patient’s peripheral blood and performing ELISA with MRSA antigens as the target antigens.
  • An isolated recombinant B lymphocyte cell line that produces two different secreted immunoglobulins to methicillin-resistant Staphylococcus aureus (MRSA) and produces a membrane immunoglobulin to a S. aureus antigen can be utilized for cell therapy in a mammalian subject.
  • the recombinant B lymphocyte cell line can be injected into the mammalian subject as cell therapy to provide immunological protection from infection by MRSA.
  • the recombinant B lymphocyte cell line can be activated in vivo or ex vivo to produce antibody to MRSA by injecting the mammalian subject (or an in vitro cell culture) with S. aureus antigen.
  • the timing to stimulate immunological protection from MRSA infection in the mammalian subject can be chosen based upon the timing of an outbreak of MRSA infection in the population at large.
  • the patient is given autologous recombinant B cells.
  • the patient’s memory B cells are genetically engineered to express two antibodies recognizing two S. aureus antigens: poly-N-acetyl glucosamine (PNAG) and immunodominant S. aureus antigen (IsaA).
  • PNAG poly-N-acetyl glucosamine
  • IsaA immunodominant S. aureus antigen
  • the recombinant memory B cells are activated and expanded in vitro in culture media (e.g, RPMI 1640, Sigma- Aldrich, St.
  • PNAG cognate antigen
  • activating cytokines e.g, interleukin-2 (Roche, Indianapolis, IN), interleukin-4, interleukin-21 and an anti-CD40 antibody (R&D Systems, Minneapolis, MN).
  • cytokines e.g, interleukin-2 (Roche, Indianapolis, IN), interleukin-4, interleukin-21 and an anti-CD40 antibody (R&D Systems, Minneapolis, MN).
  • cytokines e.g, interleukin-2 (Roche, Indianapolis, IN), interleukin-4, interleukin-21 and an anti-CD40 antibody (R&D Systems, Minneapolis, MN).
  • genomic DNA obtained from the patient’s whole blood may be used to determine the copy number of the anti-PNAG Ig genes and the anti-IsaA Ig genes per microgram of genomic DNA.
  • genomic DNA Approximately 100- 200 ng of genomic DNA is analyzed with ABI Taqman technology (available from Life Technologies Corp., Carlsbad, CA).
  • PCR primers specific for the transfected Ig genes are validated by analysis of control genomic DNA spiked with known copy numbers of the anti -A aureus Ig genes.
  • the number of genetically engineered B cells persisting in the peripheral blood may also be assessed using flow cytometry and fluorescently labeled PNAG in combination with an anti-IgG antibody.
  • an anti-IgG antibody For example, phycoerythrin (PE)- conjugated PNAG and fluorescein isothiocyanate (FITC)-conjugated anti IgG are used to stain the recombinant B cells and count them. Protocols, reagents and instrumentation for flow cytometry are available from Becton Dickinson, Franklin Lakes, NJ.
  • the level of anti-IsaA IgG (l) antibody in the patient’s peripheral blood may be analyzed using an ELISA.
  • the ELISA may be constructed with recombinant purified IsaA protein and anti-IgG or anti-l L- chain antibodies. Methods to construct and perform an ELISA are known (see e.g., Kelly-Quintos et al., Ibid.).
  • the recombinant memory B cells may be activated in vivo as well as in vitro to produce anti -A aureus antibodies.
  • the memory B cells may be activated in vivo by PNAG released from S. aureus infecting the patient or by injection of purified PNAG. Methods to purify PNAG from S. aureus are known (see e.g., Lorenz et al., Ibid).
  • the memory B cells are activated in vivo by binding of PNAG to their B cell receptors (BCR) and by interaction with T cells and cytokines (see e.g., Abbas et al., Ibid).
  • BCR B cell receptors
  • T cells and cytokines see e.g., Abbas et al., Ibid.
  • the PNAG may be administered with an immunologic adjuvant (e.g, aluminum hydroxide). Repeated activations of the memory B cells may be performed in response to recurrent MRSA infections.
  • the human patient at risk of MRSA infection is administered recombinant memory B cells as a therapeutic and prophylactic cell therapy which can be activated in vivo.
  • the recombinant memory B cells are activated in vivo by administration of PNAG antigen to the patient when an anti-MRSA antibody response is needed.
  • PNAG antigen for example, approximately 10 8 -10 9 recombinant B cells may be injected as a prophylactic when the patient is healthy or has been recently infected with MRSA.
  • the recombinant memory B cells may be activated when needed by intracutaneous injection of 100 pg of PNAG to the patient.
  • the memory B cells may be activated after the patient is exposed to MRSA or at the first signs of infection.
  • anti- MRSA antibodies may be monitored by sampling the patient’s peripheral blood and performing ELISA with MRSA antigens as the target antigens. Moreover, the presence of antibodies for MRSA can be determined by ELISA based on conserved epitopes from MRSA (see e.g., Ekiert et al., Ibid).
  • B lymphocytes produce antibodies in response to binding antigens from infectious disease microorganisms, or cancer cells, but when co-stimulated with antigens and selected cytokines they may also produce cytotoxic molecules.
  • cytotoxic molecules e.g., granzyme B
  • Cytotoxic B cells that are useful for adoptive cell therapy are constructed by engineering a recombinant B cell receptor (BCR) which recognizes a disease associated antigen and signals to elicit expression of cytotoxic effector functions.
  • BCR B cell receptor
  • a recombinant B cell receptor is constructed with a single chain antibody, membrane immunoglobulin (Ig) domains, and the cytoplasmic domain of the IL-21 receptor.
  • the single chain antibody a single chain variable fragment (SCFv)
  • SCFv is specific for a tumor associated antigen, prostate cancer lipid antigen (PCLA).
  • the SCFv is linked to membrane Ig heavy chain domains including: Hinge (H), constant region 3 (CH3), transmembrane (TM) and cytoplasmic (Cyto) domains which participate in signaling for B cell activation, and lastly, to the IL-21 receptor cytoplasmic domain which signals to elicit cytotoxicity functions from the B cell. See Fig. 8A.
  • the gene transfer and expression of the recombinant B cell receptor in these engineered B cells produces modified B cells that are responsive to the antigen PCLA.
  • the modified B cells produce cytotoxic effector molecules, such as granzyme B, and kill prostate cancer cells expressing PCLA.
  • the immunoglobulin (Ig) genes encoding an antibody that binds PCLA are isolated and engineered to construct a recombinant BCR gene for transfer and expression in a diseased subject’s own B cells.
  • PCLA a glycolipid antigen associated with prostate cancer is obtained from prostate cancer cell lines and used as an antigen. The glycolipid antigen is used to select a single chain antibody variable fragment (SCFv) which binds PCLA.
  • SCFv single chain antibody variable fragment
  • SCFv containing Ig variable region genes connected by a linker peptide have been described and can be adapted to this embodiment and methods to select antibodies from phage display single chain variable fragment (SCFv) libraries can be utilized.
  • a SCFv protein (and the corresponding SCFv gene) which avidly binds PCLA on prostate cancer cells is selected for construction of a recombinant BCR.
  • the anti-PCLA SCFv gene is attached to segments encoding domains of membrane IgGl heavy (H)-chain to create a recombinant B cell receptor.
  • the hinge segment 1008, the carboxy-terminal heavy chain constant region domain (C H 3) 1010, the transmembrane domain (TM) 1015, and the cytoplasmic domain 1020 of membrane IgGl heavy chain are encoded at the 3’end of the SCFv 1005 gene. See Figure 8A. Detailed methods to construct membrane IgG H-chains can be adapted to this embodiment.
  • the IgGl transmembrane and cytoplasmic domains are a 52 amino acid segment that interacts with the associated transmembrane B cell signaling proteins, Iga and 3 ⁇ 4b, that comprise the B cell receptor [(see e.g., Abbas et al., Cellular and Molecular Immunology, 7th Edition, pp. 159-161, 2012, Elsevier, Philadelphia, PA)].
  • the last segment of the recombinant B cell receptor contains the cytoplasmic domain of the interleukin-21 (IL-21) receptor 1025.
  • the IL-21 receptor can signal to elicit cytotoxic effector functions in B cells. For example, co-stimulation of human B cells with an anti-Ig antibody (i.e., stimulation of membrane IgG) and IL-21 elicits expression of cytotoxic effectors such as granzyme B and perforin.
  • the cytoplasmic domain of the IL- 21 receptor protein has been identified, and the structure and signaling of the IL-21 receptor have been described. See Fig. 8A for a model of the recombinant B cell receptor protein.
  • DNA segments encoding the SCFv, IgG constant domains and the IL-21 receptor cytoplasmic domain are amplified from DNA clones using the polymerase chain reaction or synthesized (e.g., Custom DNA synthesis is available from Life Technologies Corp., Grand Island, NY 14072).
  • the segment encoding the anti-PCLA SCFv may be amplified from the phage clone selected above.
  • Immunoglobulin constant region, transmembrane domain and cytoplasmic domain sequences can be synthesized by automated DNA synthesis based on publicly available sequences, and the IL-21 receptor sequence and subdomains are available.
  • the gene encoding the recombinant B cell receptor may be assembled from the DNA segments using the splice overlap extension method.
  • the recombinant B cell receptor gene is inserted in a mammalian cell expression vector for transfer into human B cells.
  • An expression vector with cytomegalovirus (CMV) promoter elements, a selectable marker gene and poly A addition signals is described. See Fig. 8B.
  • the plasmid vector directs expression of the recombinant B cell receptor under the control of the CMV promoter and carries a selectable marker gene to allow selection of B cells expressing the vector with a drug (e.g ., Neo expression confers resistance to G418; both resistance gene, Neo, and drug, G418, are available from InVivoGen, San Diego,
  • the plasmid vector encoding the recombinant B cell receptor is transfected into primary human B cells (isolated from peripheral blood) using a device, kit and protocol available from Lonza Inc., Allendale, NJ 07401 (see e.g., Human B Cell Protocol
  • Transfected, G418- resistant B cells expressing the recombinant B cell receptor are identified by flow cytometry using antibodies specific for the SCFv present in the recombinant B cell receptor.
  • PCLA antigen may be used to identify B cells expressing the recombinant B cell receptor, for example, by identifying and sorting cells by flow cytometry.
  • B cells expressing the recombinant B cell receptor are tested in vitro for cytotoxic effector function following stimulation.
  • Cytotoxic B cells expressing the anti-PCLA recombinant BCR are stimulated with antibodies specific for the SCFv or Ig H-chain constant region components (e.g., anti-human IgG) of the recombinant BCR, and cell culture supernatants are analyzed for the presence of Granzyme B by using an
  • a Granzyme B ELIspot assay kit (available from Cell Sciences, Canton, MA) may be used to determine the number of Granzyme B producing cells in a culture.
  • An Immunospot Analyzer and Immunospot 3 software (CTL Cellular Technology Ltd., Cleveland, OH) can be used to detect and count the Granzyme B producing modified B cells.
  • a flow cytometry-based assay is used to determine the percentage of target cells which are apoptotic after exposure to recombinant cytotoxic B cells. For example, approximately 250,000 recombinant cytotoxic B cells are added to 10,000 prostate cancer cells (e.g ., PC3 cell line which expresses PCLA). After co-culture for approximately 3 days, target cell (i.e., PC3) apoptosis is determined by staining with annexin V and propidium iodide; the percentage of apoptotic cells is determined by flow cytometry.
  • target cell i.e., PC3
  • apoptosis is determined by staining with annexin V and propidium iodide; the percentage of apoptotic cells is determined by flow cytometry.
  • a matched negative control culture with a target cell line not expressing PCLA is compared to the PC3 culture.
  • cultures with different ratios of effector cells (recombinant cytotoxic B cells) to target cells (PC3 cells) are analyzed.
  • Effector: Target ratios of 5: 1, 10: 1, 25: 1 and 50: 1 are analyzed for target cell apoptosis and viability.
  • a plot of target cell viability versus EffectonTarget cell ratio can indicate cytotoxic effector function by the recombinant cytotoxic B cells.
  • Modified B cells that exhibit cytotoxicity responsive to a prostate cancer tumor antigen are engineered with a recombinant B cell receptor and an inducible gene for perforin which promote cytotoxicity for the target cells.
  • Stimulation of B cells with the cytokine, interleukin-21 (IL-21) and antigen can result in the production of cytotoxic molecules (e.g., granzyme B) which may cause cell death.
  • cytotoxic molecules e.g., granzyme B
  • an important cytotoxic effector molecule may be lacking in B cells. Therefore, in order to provide coordinated production of perforin, an expression cassette for perforin is placed under the control of Ig heavy chain variable region (VH) promoter/enhancer sequences.
  • VH Ig heavy chain variable region
  • a recombinant B cell receptor is constructed with a single chain antibody, membrane immunoglobulin (Ig) domains, and the cytoplasmic domain of the IL-21 receptor.
  • the single chain antibody a single chain variable fragment (SCFv)
  • SCFv is specific for a tumor associated antigen, prostate cancer lipid antigen (PCLA).
  • the SCFv is linked to membrane Ig heavy chain domains including: Hinge (H), constant region 3 (C H 3), transmembrane (TM) and cytoplasmic domains, which participate in signaling B cell activation, and lastly, to the IL-21 receptor cytoplasmic domain which signals to elicit cytotoxicity functions from the B cell. See Fig. 8A.
  • Recombinant B cells respond to antigen (i.e., PCLA or tumor cells bearing PCLA on their surface) by signaling via the recombinant BCR to activate transcription at the active Ig H and L loci.
  • antigen i.e., PCLA or tumor cells bearing PCLA on their surface
  • signaling by the recombinant BCR via interaction with Iga and IgP may result in B cell activation and differentiation, and signaling via the IL-21 cytoplasmic domain may lead to granzyme B production.
  • the human perforin gene is introduced at the active functional Ig H chain locus under the control of the Ig V H promoter and Ig enhancer elements.
  • Cytotoxic B cells are engineered to express the human perforin gene from the active functional Ig heavy chain locus and under the control of Ig V H promoter sequences and an Ig enhancer element.
  • the gene encoding human perforin is publicly available.
  • the approximately 1668 nucleotide complementary DNA (cDNA) encoding human perforin is amplified using the polymerase chain reaction (PCR) and oligonucleotide primers to add terminal sequences homologous to 5’ and 3’ flanking sequences of the active, rearranged Ig gamma H-chain gene in the recombinant B cell line. See Fig. 3 A.
  • the perforin cDNA is amplified with a 5’ primer containing approximately 30 nucleotides homologous to upstream sequence flanking the active V H gene (see e.g., V H ID1J2 in Fig.
  • a 3’ primer containing approximately 30 nucleotides homologous to sequence downstream from the active constant region gene see e.g., CVy in Fig. 3 A.
  • the amplified perforin gene with ends homologous to the active Ig H-chain gene on chromosome 14 is integrated by homologous recombination to replace the gH chain gene (see Fig. 8C).
  • Engineering and site-specific integration of genes at the active Ig heavy chain locus in an isolated recombinant cell line are described [(see e.g., Ei.S. Patent No. 9,175,072, Ibid.)].
  • Perforin expression by transfected B cells may be determined using an Elispot assay which enumerates perforin producing cells in vitro following stimulation of the cells.
  • Materials and protocols for a human perforin Elispot assay are available from Cell Sciences, Inc., Canton, MA (see Data sheet: Human Perforin Elispot Kit, available online at
  • a flow cytometry-based assay is used to determine the percentage of target cells which are apoptotic after exposure to recombinant cytotoxic B cells. For example, approximately 250,000 recombinant cytotoxic B cells are added to 10,000 prostate cancer cells (e.g., PC3 cell line which expresses PCLA). After co-culture for approximately 3 days, target cell (i.e., PC3) apoptosis is determined by staining with annexin V and propidium iodide; the percentage of apoptotic cells is determined by flow cytometry.
  • target cell i.e., PC3
  • apoptosis is determined by staining with annexin V and propidium iodide; the percentage of apoptotic cells is determined by flow cytometry.
  • a matched negative control culture with a target cell line not expressing PCLA is compared to the PC3 culture.
  • cytotoxic B cells not transfected with the perforin gene are compared in the cytotoxicity assay.
  • Cultures with different ratios of effector cells (recombinant cytotoxic B cells) to target cells (PC3 cells) are analyzed. For example, cultures with Effector: Target ratios of 5: 1, 10: 1, 25: 1 and 50: 1 are analyzed for target cell apoptosis and viability.
  • a plot of target cell viability versus Effector: Target cell ratio can indicate cytotoxic effector function by the recombinant cytotoxic B cells.
  • Engineered B Lymphocytes Express a Recombinant B-Cell Receptor Specific for Prostate Cancer Lipid Antigen and a Secreted Antibody Specific for Prostate Specific Stem Cell Antigen.
  • An isolated recombinant B lymphocyte cell line that expresses a recombinant B cell receptor (BCR) specific for prostate cancer lipid antigen (PCLA) and secretes an antibody recognizing prostate stem cell antigen (PSCA) is constructed for therapy of prostate cancer.
  • the recombinant B lymphocyte cell line is infused in a subject to provide B cells that are not only cytotoxic for tumor cells but also produce a therapeutic antibody that recognizes prostate cancer cells.
  • Recombinant B lymphocyte cells bind PCLA on prostate cancer cells via an engineered recombinant BCR and are activated to produce cytotoxic effectors (e.g., Granzyme B) and to secrete anti-PSCA antibody.
  • cytotoxic effectors e.g., Granzyme B
  • the recombinant B cells provide cellular and humoral immunity targeted to prostate cancer cells.
  • the recombinant B lymphocyte cell line can also be stimulated in vivo or ex vivo by injecting the mammalian subject (or an in vitro cell culture) with exogenous PCLA to elicit cytotoxic effectors and to produce secreted anti-PSCA antibody. Determination of timing to stimulate immunological reactivity to prostate cancer cells in the mammalian subject can be chosen based upon the detection of prostate cancer cells in the mammalian subject.
  • Polyclonal memory B cells expressing B cell receptors (BCR) of membrane IgG are isolated from a prostate cancer patient.
  • Polyclonal memory B cells are isolated from the patient’s peripheral blood: 1) by isolating peripheral blood mononuclear cells using Ficoll Hypaque density gradients (available from Sigma Aldrich. St. Louis. Mo.); 2) by negative selection of total B cells using magnetic beads(available from Stem Cell
  • Memory B cells expressing membrane IgG are cultured in vitro and genetically engineered to express a recombinant B cell receptor and a secreted anti -PCS A antibody.
  • Memory B cells are genetically engineered to express a recombinant BCR specific for PCLA and a secreted IgG antibody specific for prostate stem cell antigen (PSCA).
  • An isolated recombinant cell line is constructed that includes a recombinant BCR.
  • the recombinant BCR binds PCLA on prostate cancer cells and signals intracellularly to the B cell to elicit expression and release of cytotoxic effector molecules such as Granzyme B as described above in Prophetic Example 6.
  • the recombinant cell line may be selected using drug selection, e.g., G418, and flow cytometry to identify clones expressing the recombinant BCR (see e.g., Prophetic Example 6 above).
  • Immunoglobulin genes encoding an anti -PSCA antibody are integrated at the active, rearranged Ig heavy chain locus on chromosome 14 (see Figure 3A), and the active, rearranged kappa light chain locus on chromosome 2, respectively.
  • Methods and materials to obtain anti-PSCA antibodies are available.
  • targeting sequences selected downstream (3’) from the yl-H chain cytoplasmic exon are placed 3' of the yl-H chain gene (see FIG. 3A).
  • Analogous targeting sequences i.e., from the Jk-Ck intron and 3' of the Ck gene
  • the targeting vectors for anti-PSCA H and L chain include selectable marker genes, e.g., hygromycin resistance and histidinol dehydrogenase, respectively.
  • Media containing hygromycin and histidinol are used to select for engineered memory B cells expressing the targeting vectors encoding a secreted IgG anti-PSCA antibody.
  • the engineered memory B cells are cultured in vitro and stimulated with PCLA to activate the cell cytotoxicity and to stimulate secretion of anti-PSCA IgG antibodies.
  • Laboratory methods to purify PCLA, the lipid antigen can be adapted for this embodiment.
  • isolated recombinant cell lines expressing the recombinant B cell receptor and anti-PSCA antibodies are tested in a cytotoxicity assay with target cells expressing PCLA and PSCA.
  • PC3 a prostate tumor cell line bearing PCLA can be transduced with a vector encoding PSCA and tested in vitro in cytotoxicity assays with engineered cytotoxic B cell lines. Methods and materials for transducing PC3 cells are described, and details of the cytotoxicity assay are described above. See Prophetic Example 6.
  • Cytotoxic B cells are produced by engineering memory B cells expressing B cell receptors (BCR) specific for prostate cancer lipid antigen (PCLA).
  • BCR B cell receptors
  • PCLA prostate cancer lipid antigen
  • the B cells are transfected with a viral vector encoding transcription factors which control the expression of cytotoxic effector molecules including granzyme B and perforin.
  • Engineered cytotoxic B cells that recognize and kill prostate cancer cells can be used for adoptive cell therapy in prostate cancer patients.
  • Memory B cells expressing B cell receptors recognizing PCLA are constructed with immunoglobulin (Ig) genes encoding an anti-PCLA antibody.
  • the engineered Ig genes are inserted at the actively transcribed heavy (H) and light (L) chain loci on human chromosomes 14 and 2.
  • Polyclonal memory B cells expressing B cell receptors (BCR) of membrane IgG are isolated from a prostate cancer patient. Polyclonal memory B cells are isolated from the patient’s peripheral blood: 1) by isolating peripheral blood mononuclear cells using Ficoll Hypaque density gradients (available from Sigma Aldrich. St. Louis.
  • Immunoglobulin genes encoding an anti-PCLA antibody are integrated at the active, rearranged Ig heavy chain locus on chromosome 14 (see Fig. 3A), and the active, rearranged kappa light chain locus on chromosome 2, respectively.
  • Anti-PCLA antibodies are obtained, and the corresponding Ig genes are isolated, engineered and site-specifically integrated at the active Ig heavy chain and light chain loci in an isolated recombinant cell line.
  • Engineered B cells expressing membrane IgG specific for PCLA are transduced with a viral vector encoding three transcription factors essential for cytotoxic B cell function. Three transcription factors regulate the expression of cytotoxic effector molecules such as granzyme B. Transcription factors: T-bet, Runx3 and Eomes are essential for the expression of granzyme B and perforin in the context of cytotoxic T cell differentiation.
  • a tricistronic vector encoding T-bet, Runx3 and Eomes is constructed using a Sendai virus vector which transduces human B cells. See Fig. 8D. Transfection and expression of the vector in the engineered B cells can be monitored by
  • cytotoxic B cells expressing membrane IgG specific for PCLA are tested for cytotoxic effector function versus prostate cancer cell lines.
  • PC3 a prostate tumor cell line bearing PCLA can be used as a target cell in a flow cytometric assay that detects apoptotic cells following exposure to the engineered cytotoxic B cells (see Prophetic Example 2 above).
  • Engineered cytotoxic B cells expressing membrane IgG recognizing PCLA can also be tested in vivo in a xenogeneic mouse model of human prostate cancer.
  • PC3 human prostate tumor cells are implanted subcutaneously in
  • mice e.g., NSG mice available from Jackson Labs, Bar Harbor, ME
  • mice are treated with the engineered cytotoxic B cells.
  • the mice are evaluated with respect to tumor size, body weight and survival.
  • Control tumor cell lines can include tumors not expressing PCLA.
  • the survival or expansion of cytotoxic B cells in the mice following infusion or injection in control mice or PC3 tumor-bearing mice is evaluated and recorded.
  • Memory B lymphocytes are isolated from a prostate cancer patient and engineered to express an anti-PCLA (prostate cancer lipid antigen) membrane Ab (antibody) and a chemokine receptor, CXCR3.
  • a gene encoding a single chain anti-PCLA Ab is integrated at the active, rearranged kappa light (L)-chain locus on chromosome 2, and disrupts endogenous Ig kappa L-chain expression.
  • the CXCR3 gene is integrated at the endogenous active, rearranged immunoglobulin (Ig) heavy (H)-chain locus and disrupts endogenous Ig H-chain expression.
  • Engineered B cells that home to prostate cancer tumors by virtue of CXCR3 -mediated chemotaxis are used for adoptive cell therapy of prostate cancer.
  • Tumor-localized, engineered B cells provide therapeutic anti-PCLA antibodies to tumor cells at elevated local concentrations.
  • Memory B cells are engineered to express a single chain membrane Ab for PCLA (prostate cancer lipid antigen) under the control of the endogenous Ig kappa promoter and/or enhancer sequences by insertion in the endogenous rearranged, active kappa light chain gene locus using CRISPR technology (Clustered Regularly Interspaced Short Palindromic Repeats).
  • the immunoglobulin (Ig) genes encoding an antibody that binds PCLA are isolated and engineered to construct a recombinant Ig gene for transfer and expression in a diseased subject’s own B cells.
  • PCLA a glycolipid antigen associated with prostate cancer is obtained from prostate cancer cell lines and used as an antigen.
  • the glycolipid antigen is used to select a single chain antibody variable fragment (SCFv) which binds PCLA.
  • SCFv containing Ig variable region genes connected by a linker peptide have been described and can be adapted to this embodiment.
  • SCFv single chain variable fragment
  • the anti-PCLA single chain Ab gene is incorporated in an AAV vector (Adeno- Associated Virus vector) and is flanked by homology arms for integration at the kappa L- chain locus on chromosome 2 (see e.g., Eyquem et ak, Nature 543, 113-117, 2017 which is incorporated herein by reference). Homology arms that target the active endogenous Ig kappa-chain gene flank the anti-PCLA Ab gene to direct integration into the kappa L- chain locus and disrupt endogenous kappa L-chain expression. See Figure 9A for more details.
  • Synthetic RNAs encoding a guide RNA targeting the integration site and a messenger RNA encoding Cas9 endonuclease are introduced by electroporation into memory B cells. Approximately 2 hours later the cells are transduced with the AAV- PCLA Ab vector.
  • Synthetic guide RNAs and Cas9 mRNA are available from Trilink Biotechnologies, San Diego, CA, and AAV vectors are available from Cell Biolabs, Inc., San Diego, CA).
  • Memory B cells are engineered to also express a gene for CXCR3 at the active Ig H-chain locus on chromosome 14. Simultaneous integration of the anti-PCLA Ab and CXCR3 genes using CRISPR technology can be performed to expedite and optimize engineering of memory B cells (see e.g., Le Cong et ak, Science 339: 819-823, 2013 which is incorporated herein by reference).
  • a gene encoding CXCR3 is available from GenScript, Piscataway, NJ.
  • AAV vector is designed to encode the human CXCR3 gene flanked by homology arms targeting the Ig H-chain CH1 exon on Chromosome 14, in order to disrupt the active Ig H-chain gene and insert a functional CXCR3 gene. See Figure 9B for more details.
  • Synthetic RNAs encoding guide RNAs targeting the integration site and a messenger RNA encoding Cas9 endonuclease are introduced by electroporation into memory B cells isolated from the prostate cancer patient. Approximately 2 hours later the cells are transduced with the AAV-CXCR3 vector.
  • Synthetic guide RNAs and Cas9 mRNA are available from Trilink Biotechnologies, San Diego, CA, and AAV vectors are available from Cell Biolabs, Inc., San Diego, CA).
  • B cells are grown in vitro using culture media containing cytokines such as IL-21 and co-stimulators such as oligodeoxynucleotide, CpG and anti-CD40 Ab (see e.g., Kwakkenbos et ah, Nature Medicine 16: 123-128, 2010 which is incorporated herein by reference).
  • cytokines such as IL-21
  • co-stimulators such as oligodeoxynucleotide, CpG and anti-CD40 Ab
  • B cells expressing CXCR3 from the disrupted Ig H-chain locus are identified and isolated using flow cytometry.
  • B cells that stain with fluorescent anti-CXCR3 Ab and are not stained by fluorescent anti-IgM antibody are selected by cell sorting and cultured in vitro. Fluorescent anti-CXCR3 and anti-human IgM Abs are available from ABCAM, Cambridge, MA.
  • B cells staining positive with CXCR3 Ab are tested in vitro for expression of CXCR3 mRNA using RT-PCR; B cells negative for CXCR3 and/or positive for IgM are tested as negative controls.
  • Each B cell sample is tested plus and minus stimulation with B cell activators (e.g., IL-21, anti-CD40 and CpG).
  • B cell activators e.g., IL-21, anti-CD40 and CpG
  • an in vitro chemotaxis assay is performed with CXCL10, a ligand for CXCR3.
  • Engineered B cells are introduced onto a permeable membrane in a transwell plate.
  • the chamber below the membrane is filled with culture medium containing CXCL10 and following incubation for several hours the migration of engineered B cells to the lower chamber is scored by staining the B cells in situ.
  • Control plates omit CXCL10, or use non-transfected B cells or IgM-positive B cells.
  • the recombinant memory B cells are activated and expanded in vitro in culture media (e.g., RPMI 1640, Sigma-Aldrich, St. Louis, MO) containing: cognate antigen, PCLA, at approximately 100 ng/mL and activating cytokines, e.g, interleukin-2 (Roche, Indianapolis, IN), interleukin-4, interleukin-21 and an anti-CD40 antibody (R&D Systems, Minneapolis, MN).
  • culture media e.g., RPMI 1640, Sigma-Aldrich, St. Louis, MO
  • cytokines e.g, interleukin-2 (Roche, Indianapolis, IN), interleukin-4, interleukin-21 and an anti-CD40 antibody (R&D Systems, Minneapolis, MN).
  • the memory B cells are harvested, washed and concentrated prior to infusion in the patient. Approximately 5 x 10 8 recombinant B cells are infused and the expansion and persistence of the recombinant B cells are followed by sampling the patient’s peripheral blood. Methods to infuse and track genetically engineered lymphocytes are described (see e.g., Kalos et al., Sci. Transl. Med. 3, 95ra73, 2011; DOI: 10. H26/scitranslmed.3002842 which is incorporated herein by reference).
  • Memory B lymphocytes obtained from a patient with multiple sclerosis are engineered to express a membrane antibody (Ab) that recognizes myelin oligodendrocyte glycoprotein (MOG), and to produce an anti-inflammatory cytokine, interleukin 10 (IL- 10).
  • the engineered B cells bind MOG and respond by producing IL-10.
  • a gene for an anti-MOG membrane Ab is expressed under the control of a constitutive promoter, and a gene encoding IL-10 is integrated at the endogenous Ig heavy (H)-chain locus of memory B cells and expressed under the control of the endogenous rearranged immunoglobulin variable heavy (VH) promoter and/or enhancer elements.
  • a gene encoding IL-10 is inserted at the endogenous active Ig H-chain locus on chromosome 14 using CRISPR technology.
  • a complementary DNA (cDNA) encoding human IL-10 (available from Harvard Medical School, Boston, MA) is incorporated in an adenovirus associated virus (AAV) vector (e.g., AAV vectors are available from Cell Biolabs, Inc., San Diego, CA).
  • AAV adenovirus associated virus
  • the human IL-10 cDNA is flanked by a splice acceptor (SA) sequence, a poly A addition site (pA) and homology arms (HA) to target recombination at the Ig H-chain locus on Chromosome 14. See Figure 12A for more details.
  • SA splice acceptor
  • pA poly A addition site
  • HA homology arms
  • a guide RNA targeting the CHpl exon of the m H-chain gene results in a double- stranded DNA break that disrupts m H-chain expression and promotes insertion of the IL- 10 gene. See Figure 12A for more details.
  • RNAs for targeted insertion are described (see e.g., Eyquem et al., Ibid and Zheng et al., BioTechniques 57: 115-124, 2014 which is incorporated herein by reference), and synthetic guide RNAs and Cas9 mRNA are available from Trilink Biotechnologies, San Diego, CA.
  • Memory B cells expressing membrane IgM are obtained and purified from the peripheral blood of a MS patient. Memory B cells are obtained by cell sorting using anti-IgM and anti-CD27 antibodies. For example, see Tangye et al., J. Immunology 179, 13-19, 2007 which is incorporated herein by reference).
  • a lentiviral vector is constructed to direct expression of an anti-MOG membrane Ab on memory B cells.
  • a single chain, membrane Ab gene may be constructed with a gene encoding a human single chain variable fragment (SCFv) specific for MOG (obtained from a SCFv phage library).
  • SCFv human single chain variable fragment
  • the SCFv gene is joined to a human Ig g 1 constant region gene which includes: the hinge region, C H !-C H 3, the transmembrane domain (TM) and the cytoplasmic tail (Cyto) (see e.g., Xu et al., Cell Research 24, 651- 654, 2014 which is incorporated herein by reference). See Figure 12B.
  • the anti-MOG membrane Ig gene is preceded by a constitutive promoter, (e.g., the human cytomegalovirus promoter (CMV) and cloned in a lentiviral vector suitable for transduction of B lymphocytes (see e.g., Bovia et al., Blood 101, 1727-1733, 2003 which is incorporated herein by reference).
  • a constitutive promoter e.g., the human cytomegalovirus promoter (CMV) and cloned in a lentiviral vector suitable for transduction of B lymphocytes
  • CMV human cytomegalovirus promoter
  • Engineered B cells expressing a membrane IgG specific for MOG are tested in vitro to assess functionality.
  • the engineered B cells are grown with media containing MOG glycoprotein to activate their membrane IgG receptors and media samples are collected and assayed for IL-10.
  • Control cultures containing human serum albumin, or no additional protein are also tested.
  • Positive control cultures containing anti human IgG are also tested for IL-10 concentration.
  • CRISPR/Cas9 technology including specific guide RNAs restricts DNA DS breaks and gene insertion to the rearranged g H-chain gene expressed by each IgG-positive memory B cell.
  • a bicistronic gene composed of a recombinant BCR gene and a gene for IL-21 are inserted in the rearranged, active g H-chain gene on chromosome 14 in IgG-positive memory B cells.
  • Polyclonal memory B cells expressing membrane IgG are isolated from the peripheral blood of a patient using magnetic bead separations and flow cytometry to isolate IgG-positive, CD27-positive, B cells (see e.g., Ettinger et ah, Ibid and Brown et ah, Ibid).
  • Targeted disruption and integration at multiple different active Ig g H-chain genes is accomplished using a CRISPR/Cas9 system with two guide RNAs and a template gene for homologous recombination. Methods and materials to delete a DNA segment and replace it with donor gene(s) of interest are described (see e.g., Zheng et ah,
  • gRNAs guide RNAs targeting two conserved sites in each rearranged g H- chain gene are designed to target: (1) a site in VDJ-Cy intron which is downstream (3’) of the Ig mu enhancer (pEnh) but upstream (5’) of the class switch recombination site (CSRS); and (2) a site near the first exon (CHyl) of the g constant region gene. See Fig 13 for more details.
  • An AAV vector containing a bicistronic DNA construct encoding a recombinant BCR and IL-21 is constructed with homology arms that flank the deletion in the g l-H chain gene. See Fig. 13 for more details.
  • a P2a peptide is encoded 5’ of the BCR and the IL-21 genes.
  • Bicistronic constructs with P2a self-cleaving peptides are described (see e.g., Kim et ah, PLoS ONE 6(4): el8556, 2011; doi: l0.l37l/journal. pone.0018556 which is incorporated herein by reference).
  • the recombinant BCR may be constructed from a broadly neutralizing Ab for HIV (see e.g., Balazs et al., Nature 481, 81-84, 2012 which is incorporated herein by reference) and expressed as a single chain variable fragment (SCFV).
  • SCFV single chain variable fragment
  • the engineered memory B cells are incubated with HIV envelope protein and media samples are collected at 1, 2, 4, and 8 hours and the amount of IL-21 is determined using an immunoassay (e.g., enzyme-linked immunosorbent assay, (ELISA)).
  • An IL-21 ELISA kit is available from RayBiotech, Inc., Norcross, GA.
  • Negative control cultures without HIV env protein or with a control protein, (e.g., human serum albumin) are compared to the HIV env-stimulated cultures. Positive control cultures are run using anti- IgG antibodies to stimulate the engineered B cells.
  • Engineered memory B cells are tested for cytotoxic effector function in vitro using engineered mammalian cells expressing HIV env protein.
  • a mammalian cell line e.g., HEK 293 is transfected with an expression vector encoding HIV-l gp4l (gp4l cDNA is available from Bioclone Inc., San Diego, CA) and a cell line (gp4l/HEK) expressing gp4l on the cell surface is selected using an anti-gp4l monoclonal antibody, Mab.
  • Co-culture of engineered memory B cells with gp4l/HEK target cells is followed by monitoring cell viability, e.g., Trypan Blue staining, assessing apoptosis and measuring release lactic dehydrogenase.
  • the release of Granzyme B into the media can be measured using an ELISA.
  • the cellular cytotoxicity measured against gp4l/HEK cells versus control HEK 293 cells is obtained at various ratios of cytotoxic B cell effectors to target cells (e.g., 1 : 1, 2: 1, 4: 1, 10: 1, 20: 1, 40: 1).
  • Each recited range includes all combinations and sub-combinations of ranges, as well as specific numerals contained therein.
  • the surgeon may opt for a mainly hardware and/or firmware vehicle; alternatively, if flexibility is paramount, the implementer may opt for a mainly software implementation; or, yet again alternatively, the implementer may opt for some combination of hardware, software, and/or firmware.
  • any vehicle to be utilized is a choice dependent upon the context in which the vehicle will be deployed and the specific concerns (e.g., speed, flexibility, or predictability) of the implementer, any of which may vary.
  • Those having ordinary skill in the art will recognize that optical aspects of implementations will typically employ optically-oriented hardware, software, and or firmware.
  • “electrical circuitry” includes, but is not limited to, electrical circuitry having at least one discrete electrical circuit, electrical circuitry having at least one integrated circuit, electrical circuitry having at least one application specific integrated circuit, electrical circuitry forming a general purpose computing device configured by a computer program (e.g, a general purpose computer configured by a computer program which at least partially carries out processes and/or devices disclosed herein, or a microdigital processing unit configured by a computer program which at least partially carries out processes and/or devices disclosed herein), electrical circuitry forming a memory device (e.g, forms of random access memory), and/or electrical circuitry forming a communications device (e.g, a modem, communications switch, or optical- electrical equipment).
  • the subject matter disclosed herein may be implemented in an analog or digital
  • a data processing system generally includes one or more of a system unit housing, a video display device, memory such as volatile or non volatile memory, processors such as microprocessors or digital signal processors, computational entities such as operating systems, drivers, graphical user interfaces, and applications programs, one or more interaction devices (e.g ., a touch pad, a touch screen, an antenna, etc.), and/or control systems including feedback loops and control motors (e.g., feedback for sensing position and/or velocity; control motors for moving and/or adjusting components and/or quantities).
  • a data processing system may be implemented utilizing suitable commercially available components, such as those typically found in data computing/communication and/or network computing/communication systems.
  • ASICs Integrated Circuits
  • FPGAs Field Programmable Gate Arrays
  • DSPs digital signal processors
  • embodiments disclosed herein, in whole or in part, can be equivalently implemented in integrated circuits, as one or more computer programs running on one or more computers (e.g, as one or more programs running on one or more computer systems), as one or more programs running on one or more processors (e.g, as one or more programs running on one or more microprocessors), as firmware, or as virtually any combination thereof, and that designing the circuitry and/or writing the code for the software and or firmware would be well within the skill of one of skill in the art in light of this disclosure.
  • a signal bearing medium examples include, but are not limited to, the following: a recordable type medium such as a floppy disk, a hard disk drive, a Compact Disc (CD), a Digital Video Disk (DVD), a digital tape, a computer memory, etc.; and a transmission type medium such as a digital and/or an analog communication medium (e.g, a fiber optic cable, a waveguide, a wired communications link, a wireless communication link ( e.g ., transmitter, receiver, transmission logic, reception logic, etc.), etc.).
  • a signal bearing medium include, but are not limited to, the following: a recordable type medium such as a floppy disk, a hard disk drive, a Compact Disc (CD), a Digital Video Disk (DVD), a digital tape, a computer memory, etc.; and a transmission type medium such as a digital and/or an analog communication medium (e.g, a fiber optic cable, a waveguide, a wired communications link, a wireless communication
  • any two components so associated can also be viewed as being “operably connected,” or“operably coupled,” to each other to achieve the desired functionality, and any two components capable of being so associated can also be viewed as being“operably couplable,” to each other to achieve the desired functionality.
  • operably couplable include but are not limited to physically mateable or physically interacting components or wirelessly interactable or wirelessly interacting components or logically interacting or logically interactable components.
  • recombinant B cell receptor that is capable of binding to a first antigen; at least one exogenously incorporated reassigned biological agent;
  • chromosomal loci are located on the non-expressed Ig allele.
  • the isolated modified B cell of clause 8 wherein the integration at the kappa or lambda light (L)-chain locus disrupts endogenous B cell kappa or lambda light (L)- chain expression.
  • the chromosomal loci include one or more non-Ig L or non-Ig H chromosomal loci in the isolated B lymphocyte cell line.
  • exogenous nucleic acid encoding the exogenous membrane immunoglobulin includes disruption of expression of the B cell endogenous immunoglobulin.
  • cytotoxic effector molecules include at least one of perforin, granzyme b, Fas ligand, or tumor necrosis factor- related apoptosis-inducing ligand (TRAIL).
  • immunoglobulin capable of binding to a second antigen.
  • the isolated modified B cell of clause 34 wherein the Ig L chain locus includes at least one of the kappa or the lambda light (L)-chain locus.
  • the isolated modified B cell of clause 36 wherein the integration at the kappa or lambda light (L)-chain locus disrupts endogenous B cell kappa or lambda light (L)- chain expression.
  • the isolated modified B cell of clause 32 wherein the at least one exogenously incorporated nucleic acid encoding the at least one exogenous membrane immunoglobulin is incorporated in an extrachromosomal replicating genetic element in the isolated modified B cell.
  • the isolated modified B cell of clause 32 wherein the at least one exogenously incorporated membrane immunoglobulin activated by the first antigen is capable of controlling production of the at least one exogenous secreted immunoglobulin reactive to the second antigen.
  • the isolated modified B cell of clause 44, wherein the at least one exogenously incorporated membrane immunoglobulin includes nucleic acids encoding two heavy chain (H) immunoglobulins and two light chain (L) immunoglobulins.
  • cytotoxic effector molecules include at least one of perforin, granzyme B, Fas ligand, or tumor necrosis factor- related apoptosis-inducing ligand (TRAIL).
  • the isolated modified B cell of clause 54 wherein the cytotoxic effector molecules are expressed in response to a specific target cell or target antigen.
  • the at least one exogenously incorporated secreted immunoglobulin includes at least one exogenously incorporated secreted immunoglobulin polypeptide.
  • immunoglobulin is incorporated in an extrachromosomal replicating genetic element in the isolated modified B cell.
  • exogenous nucleic acid encoding the exogenous secreted immunoglobulin includes disruption of expression of the B cell endogenous immunoglobulin H-chain and/or L-chain.
  • immunoglobulin is derived from a B lymphocyte cell.
  • An isolated modified B cell capable of expressing at least one exogenously
  • cytotoxic effector molecule configured to directly or indirectly induce at least one cytotoxic effector molecule includes at least one chimeric receptor exhibiting at least a portion of at least one cytokine receptor.
  • An isolated modified B cell capable of expressing at least one exogenously
  • cytotoxic effector molecule configured to directly or indirectly induce at least one cytotoxic effector molecule includes at least one chimeric receptor exhibiting at least a portion of at least one cytokine receptor.
  • the reassigned biological agent includes at least one cytokine, chemokine, cytotoxin, receptor, or ligand.
  • the isolated modified B cell of clause 80 wherein the isolated modified B cell is capable of expressing at least one exogenously incorporated membrane receptor configured to directly or indirectly induce expression of at least one cytotoxic effector molecule.
  • the isolated modified B cell of clause 80 wherein the isolated modified B cell is capable of expressing at least one exogenously incorporated membrane immunoglobulin or a recombinant B cell receptor that is reactive to a first antigen.
  • a method comprising:
  • an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin or a recombinant B cell receptor that is capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding capable of binding to a second antigen;
  • At least one exogenous nucleic acid encoding at least one reassigned biological agent at least one exogenous nucleic acid encoding at least one reassigned biological agent.
  • an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin or a recombinant B cell receptor that is capable of binding to a first antigen and at least one exogenous secreted immunoglobulin capable of binding capable of binding to a second antigen;
  • At least one exogenous nucleic acid encoding at least one reassigned biological agent at least one exogenous nucleic acid encoding at least one reassigned biological agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et des procédés pour la production d'une ou de plusieurs immunoglobulines dans une lignée cellulaire isolée cytotoxique de lymphocytes B. Une lignée cellulaire isolée comprend une lignée cellulaire de lymphocytes B isolée capable d'exprimer au moins une immunoglobuline membranaire incorporée de manière exogène capable de se lier à un premier antigène et au moins une immunoglobuline sécrétée endogène capable de se lier à un deuxième antigène, et en outre capable d'exprimer au moins un récepteur de lymphocytes B recombinant incorporé de manière exogène qui signale l'expression de molécules effectrices cytotoxiques.
PCT/US2019/022572 2018-03-19 2019-03-15 Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués WO2019182910A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201980030908.8A CN112105641A (zh) 2018-03-19 2019-03-15 用于经修饰的b细胞表达重新分配的生物剂的组合物和方法
EP19771532.9A EP3768707A4 (fr) 2018-03-19 2019-03-15 Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/924,898 2018-03-19
US15/924,898 US10745468B2 (en) 2011-12-22 2018-03-19 Compositions and methods for modified B cells expressing reassigned biological agents

Publications (1)

Publication Number Publication Date
WO2019182910A1 true WO2019182910A1 (fr) 2019-09-26

Family

ID=67986343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/022572 WO2019182910A1 (fr) 2018-03-19 2019-03-15 Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués

Country Status (3)

Country Link
EP (1) EP3768707A4 (fr)
CN (1) CN112105641A (fr)
WO (1) WO2019182910A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050170398A1 (en) * 2002-07-18 2005-08-04 Van Berkel Patrick Hendrikus C. Recombinant production of mixtures of antibodies
WO2010070263A1 (fr) * 2008-12-18 2010-06-24 Erasmus University Medical Center Rotterdam Animaux transgeniques non humains exprimant des anticorps humanises et leur utilisation
WO2011050985A1 (fr) * 2009-10-30 2011-05-05 Biontech Ag Expansion clonale de lymphocytes b
WO2013096568A1 (fr) * 2011-12-22 2013-06-27 Elwha Llc Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline de membrane différente d'une immunoglobuline secrétée
US20180215817A1 (en) * 2011-12-22 2018-08-02 Elwha Llc Compositions and methods for modified b cells expressing reassigned biological agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010010387A (es) * 2008-04-02 2010-10-15 Macrogenics Inc Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
US20110302665A1 (en) * 2008-07-02 2011-12-08 Oktay Kirak Non-human mammals with t or b cells having predefined specificity
US9175072B2 (en) * 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10233424B2 (en) * 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
EP3277823B1 (fr) * 2015-04-03 2023-09-13 Dana-Farber Cancer Institute, Inc. Composition et procédés de correction génomique de cellules b
EP3469069A4 (fr) * 2016-06-10 2020-01-22 Kota Biotherapeutics, LLC Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline membranaire différente d'une immunoglobuline sécrétée et fonction cytolytique
CA3039774A1 (fr) * 2016-10-10 2018-04-19 The National Institute for Biotechnology in the Negev Ltd. Cellules modifiees non cytotoxiques et leur utilisation
US11793833B2 (en) * 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
KR20230006821A (ko) * 2020-03-31 2023-01-11 워킹 피쉬 테라퓨틱스 변형 b 세포 및 이의 사용 방법
JP2024532851A (ja) * 2021-08-18 2024-09-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｂ細胞受容体に特異的なキメラ抗原受容体のための組成物および方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050170398A1 (en) * 2002-07-18 2005-08-04 Van Berkel Patrick Hendrikus C. Recombinant production of mixtures of antibodies
WO2010070263A1 (fr) * 2008-12-18 2010-06-24 Erasmus University Medical Center Rotterdam Animaux transgeniques non humains exprimant des anticorps humanises et leur utilisation
WO2011050985A1 (fr) * 2009-10-30 2011-05-05 Biontech Ag Expansion clonale de lymphocytes b
WO2013096568A1 (fr) * 2011-12-22 2013-06-27 Elwha Llc Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline de membrane différente d'une immunoglobuline secrétée
US20180215817A1 (en) * 2011-12-22 2018-08-02 Elwha Llc Compositions and methods for modified b cells expressing reassigned biological agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of EP3768707A4 *
VETTERMANN, C. ET AL.: "Allelic exclusion of immunoglobulin genes: models and mechanisms", IMMUNOLOGICAL REVIEWS, vol. 237, 2010, pages 22 - 42, XP055536935, doi:10.1111/j.1600-065X.2010.00935.x *
XU, H. ET AL.: "Development and characterization of anti-Gal B cell receptor transgenic Gal-/- mice", TRANSPLANTATION, vol. 73, no. 10, 27 May 2002 (2002-05-27), pages 1549 - 1557, XP008174193, doi:10.1097/00007890-200205270-00006 *

Also Published As

Publication number Publication date
EP3768707A1 (fr) 2021-01-27
EP3768707A4 (fr) 2022-01-26
CN112105641A (zh) 2020-12-18

Similar Documents

Publication Publication Date Title
US11993646B2 (en) Compositions and methods for modified b cells expressing reassigned biological agents
US11180729B2 (en) Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
JP7344898B2 (ja) 養子注入されたｔ細胞の持続性を増強する方法
JP2021113200A (ja) 能動的細胞免疫療法のためのサイトカイン組成物を用いたリンパ球の増殖
US9901598B2 (en) Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
WO2014037422A1 (fr) Expansion sélective et régulée de cellules nk éduquées
JP5641599B2 (ja) 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤
CA2413866A1 (fr) Compositions et procedes relatifs a des anticorps monoclonaux et polyclonaux propres a des sous populations de cellules t
US9512213B2 (en) Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
WO2017214376A1 (fr) Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline membranaire différente d'une immunoglobuline sécrétée et fonction cytolytique
CN112969470A (zh) 用于扩增抗原特异性car-t细胞、组合物的方法及其相关用途
CN111683971A (zh) 医药重组受体组成物及方法
US20070128670A1 (en) Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and use thereof
WO2019182910A1 (fr) Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19771532

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019771532

Country of ref document: EP

Effective date: 20201019